lincRNA-DEFICIENT NON-HUMAN ANIMALS
By creating non-human animals with non-functional lncRNAs through knockout methods, specific phenotypes related to lncRNA dysfunction are achieved, addressing the need for manipulating these RNAs and providing models for studying their functions.
Patent Information
- Application Number
- JP2024146626
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2013-08-07
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for methods and compositions to manipulate long non-coding RNAs (lncRNAs) in non-human animals to generate specific phenotypes, as the functions of most lncRNAs are unknown, and existing technologies lack effective ways to manipulate these RNAs to achieve desired outcomes.
The development of non-human animals, cells, and tissues with non-functional lncRNAs, including knockouts, and the use of targeting compositions to modify or knockout lncRNAs, resulting in phenotypes such as premature aging, muscle loss, and developmental defects by disrupting or knocking out lncRNA function.
This approach allows for the generation of non-human animals exhibiting specific phenotypes associated with lncRNA dysfunction, providing models for studying premature aging, brain development, and other biological processes, and enabling the investigation of lncRNA functions in vivo.
Smart Images

Figure 2024164230000003 
Figure 2024164230000004 
Figure 2024164230000005
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 61 / 863,147, filed Aug. 7, 2013, which is incorporated by reference in its entirety.
[0002] Reference to sequence listing submitted as a text file via EFS Web The official copy of the sequence listing is named 448071SEQLIST.TXT and is available at The Sequence Listing was created on Aug. 7, 2007, and is 1 kilobyte in size, and has been submitted electronically via EFS Web and filed concurrently herewith. The Sequence Listing contained in this ASCII formatted document is a part of the specification and is incorporated herein by reference in its entirety.
[0003] FIELD OF THEINVENTION Non-human animals, cells, and tissues that contain one or more deletions in long non-coding RNAs ("lcnRNAs"), and methods for making same. Non-human animals that contain a non-functional lncRNA or a knockout of one or more lncRNAs, and methods for making same. Genetically modified non-human animals that exhibit a phenotype consistent with premature aging. [Background technology]
[0004] 2. Background of the Invention Long non-coding RNAs (lncRNAs) and subclasses known as long intergenic non-coding RNAs (lincRNAs) comprise approximately 15,000 diverse transcripts in mammals that resemble mRNAs in terms of their gene structure, synthesis, and chromatin characteristics. The function or phenotype associated with a particular lncRNA is unknown for the majority of identified lncRNAs. Some lncRNAs are believed to be involved in transcriptional regulation in animals as activators or repressors of transcription, while others function post-translationally or by some other mechanism. Thus, the ability to manipulate lncRNAs can provide a tool to express phenotypes of interest, depending on the identity and function of the lncRNA. There is a need in the art for methods and compositions to manipulate lncRNAs and to generate phenotypes in non-human animals through lncRNA manipulation. Summary of the Invention [Means for solving the problem]
[0005] Non-human animals, cells, tissues, and embryos are provided that include non-functional long non-coding RNAs (lncRNAs), including but not limited to knockouts of one or more lncRNAs. Methods and compositions are provided for manipulating lncRNA expression. Targeting compositions for modifying or knocking out lncRNAs are also provided. Non-human animals, cells, and tissues are provided that exhibit phenotypes associated with non-function of one or more lncRNAs.
[0006] In one embodiment, a non-human animal is provided that comprises at least one modified lncRNA in its genome, where the modified lncRNA locus comprises a loss-of-function mutation in a nucleic acid sequence encoding the lncRNA.
[0007] In one embodiment, the lncRNA is a long intergenic non-coding RNA (lincRNA).
[0008] In one embodiment, the loss-of-function mutation is characterized by the disruption or knockout of at least one lncRNA function.
[0009] In one embodiment, the modified lncRNA locus comprises a deletion of one or more exons comprising the lncRNA or a portion thereof. In one aspect, the disruption or knockout comprises a deletion of one or more exons in the lncRNA gene starting within the second exon of the lncRNA locus, a deletion of one or more exons in the lncRNA locus starting within the first exon of the lncRNA locus, or a deletion of the entire RNA coding region of the lncRNA locus.
[0010] In one aspect, the disruption or knockout comprises replacing the lncRNA locus or a portion thereof with an insert nucleic acid. In one embodiment, the insert nucleic acid comprises a first nucleotide sequence encoding a reporter. In such a case, the first nucleotide sequence is operably linked to a promoter that drives the expression of the reporter. In one embodiment, the first nucleotide sequence encoding the reporter is located within the lncRNA locus that is operably linked to an endogenous lncRNA promoter. Here, the endogenous lncRNA promoter drives the expression of the nucleotide sequence. In such a case, the expression of the nucleic acid sequence follows the expression pattern of the lncRNA. In one aspect, the insert nucleic acid comprises a Kozak consensus sequence. In a specific embodiment, the first nucleotide sequence of the insert nucleic acid comprises a Kozak consensus sequence.
[0011] In one embodiment, the insert nucleic acid further comprises a second nucleotide sequence encoding a selectable marker, wherein the second nucleotide sequence is operably linked to a promoter.
[0012] In one embodiment, the insert nucleic acid contains site-specific recombination sites flanking the segment encoding the reporter and / or the segment encoding the selectable marker.
[0013] In various aspects and embodiments, the replacement of the lncRNA locus or a portion thereof includes replacing one or more exons in the lncRNA locus starting within the second exon of the lncRNA locus with the insert nucleic acid, replacing one or more exons in the lncRNA locus starting within the first exon of the lncRNA locus with the insert nucleic acid, or replacing the entire RNA coding region of the lncRNA locus with the insert nucleic acid.
[0014] In one embodiment, the non-human animals provided herein are characterized as having one or more of the following phenotypes: (a) a premature aging-associated phenotype; (b) perinatal lethality; (c) defects in lung development; (d) morphological malformations of the tail and hind limbs; (e) loss of muscle mass in one or more tissues; or (f) any combination thereof.
[0015] In one aspect, a non-human animal provided herein comprises a disruption or knockout of lncRNA Pint, wherein the non-human animal is characterized by premature aging-associated phenotypes including: (a) slower growth rate than wild-type controls, (b) reduced muscle strength, (c) fibrosis, (d) lower body fat content than wild-type controls, (e) lower femoral bone mineral density and bone mass than wild-type controls, (f) reduced muscle mass compared to wild-type controls, (g) reduced median life span, (h) lordokyphosis, (i) organ atrophy, or (j) any combination thereof of (a)-(i).
[0016] In one embodiment, the non-human animal provided herein exhibits defects in brain development. In such cases, the lncRNA is Pantr2, Kantr, Peril, Celrr, Pantr1, Crnde, lincenc1, Pint, lincppara, or Tug1.
[0017] In various aspects and embodiments, the non-human animal is a mammal. In various aspects and embodiments, the mammal is a rodent, such as a mouse, a rat, or a hamster. In various aspects and embodiments, the mammal is an ovine, bovine, or porcine species.
[0018] In one aspect, a genetically modified non-human animal is provided, wherein the genetic modification results in a loss of function of a lncRNA.
[0019] In one embodiment, a genetically modified non-human animal is provided, wherein the genetic modification comprises a disruption or knockout of one or more lncRNAs.
[0020] In one embodiment, the genetic modification comprises the disruption or knockout of at least two lncRNAs. In one embodiment, the genetic modification comprises the disruption or knockout of at least three, four, five, or six lncRNAs.
[0021] In one embodiment, the genetic modification comprises the disruption or knockout of one or more lncRNAs, within the lncRNA locus, a gene encoding a detectable moiety (reporter) is operably linked to the promoter of the disrupted or knocked out lncRNA. The offspring are selected from lacZ (encoding β-galactosidase), GFP, eGFP, mPlum, mCherry, tdTomato, mStrawberry, J-Red, DsRed, mOrange, mKO, mCitrine, Venus, YPet, enhanced yellow fluorescent protein (EYFP), Emerald, CyPet, cyan fluorescent protein (CFP), Cerulean, T-Sapphire, luciferase, alkaline phosphatase, and combinations thereof.
[0022] In one embodiment, the genetic modification comprises the disruption or knockout of one or more lncRNAs, where in the lncRNA locus, a gene encoding a detectable moiety (reporter) is operably linked to a promoter that drives expression of the detectable moiety.
[0023] In various aspects and embodiments, the detectable moiety comprises any reporter gene known in the art.
[0024] In one aspect, a genetically modified non-human animal is provided, wherein the genetic modification is HOTAIR, HOTTIP, Hoxa11os (formerly known as HoxA11as), Pantr1 (formerly known as lincRNA-Brn1-a), Pantr2 (formerly known as lincRNA-Brn1-b), Ptgs2os2 (formerly known as lincRNA-Cox2), Eldr (formerly known as Fabl and lincRNA-Egfr), Lincenc1 (formerly known as lincRNA-Enc1), Mannr (formerly known as lincRNA-Evi1), Fendrr (formerly known as lincRNA-Foxf1), Halr1 (formerly known as Haunt and lincRNA-HoxA1), Haglr (formerly known as lincRNA-Hox D3), Celrr (formerly named Celr and lincRNA-Insig2), Crnde (formerly named lincRNA-Irx5), Kantr (formerly named Spasm and linRNA-Jarid1c), Pint (formerly named linc-Pint and lincRNA-Mkln1), Trp53cor1 (formerly named lincRNA-p21), lincppara (formerly named lincRNA-Ppara), Peril (formerly named lincENA-Sox2), Tug1 (formerly named lincRNA-Tug1), and combinations thereof.
[0025] In one aspect, a genetically modified non-human animal is provided, wherein the genetic modification comprises a disruption or knockout of Pint (formerly known as linc-Pint and lincRNA-Mkln1).
[0026] In one aspect, a nucleic acid locus is provided, comprising a disruption of an lncRNA. In one embodiment, the disruption comprises a knockout of the lncRNA. In one embodiment, the disruption comprises the arrangement of a gene encoding a detectable moiety operably linked to a promoter of the lncRNA. In one embodiment, the disruption comprises the knockout of the lncRNA and the arrangement of a gene encoding a detectable moiety operably linked to a promoter of the lncRNA.
[0027] In one embodiment, a nucleic acid construct is provided that includes at least one targeting sequence that targets the construct to a locus that contains an IncRNA, where the construct can disrupt transcription of the lncRNA, knock out the lncRNA, or replace the lncRNA.
[0028] In one embodiment, the nucleic acid construct further comprises a detectable moiety (with or without an added promoter driving expression of the detectable moiety). In one embodiment, the nucleic acid construct further comprises a selectable marker driven by a promoter. In one embodiment, the nucleic acid construct comprises both a detectable moiety (with or without its own promoter) and a selectable marker driven by a promoter. In one embodiment, the selectable marker and / or detectable moiety are flanked upstream and downstream by site-specific recombination sites that direct removal of the detectable moiety and / or selectable marker.
[0029] In one embodiment, a targeting vector is provided. In one aspect, the targeting vector comprises an insert nucleic acid flanked by 5' and 3' homology arms capable of homologous recombination with a lncRNA locus of interest. In one embodiment, the insert nucleic acid of the targeting vector comprises a first nucleic acid sequence encoding a reporter. In one aspect, following homologous recombination with the lncRNA locus of interest, the first nucleic acid sequence encoding the reporter is operably linked to an endogenous promoter driving expression of the lncRNA at the lncRNA locus. In one embodiment, the first and / or second nucleic acid sequence of the insert nucleic acid of the targeting vector further comprises a Kozak consensus sequence. In one embodiment, the targeting vector further comprises a promoter driving expression of the promoter.
[0030] In one aspect, the insert nucleic acid of the targeting vector further comprises a second nucleic acid sequence encoding a selectable marker, wherein the second nucleic acid sequence is operably linked to a promoter. In one embodiment, the targeting vector further comprises site-specific recombination sites flanking the reporter-encoding segment and / or the selectable marker nucleic acid.
[0031] In one aspect, a non-human animal is provided that exhibits a premature aging-associated phenotype. The non-human animal comprises a modification that renders Pint non-functional. In one embodiment, the modification is a disruption of the RNA coding sequence of the Pint locus. In one embodiment, the modification is a deletion of the entire RNA coding sequence of the Pint locus. In one embodiment, the modification comprises inserting a targeting vector into the Pint locus such that the animal is no longer able to make functional Pint.
[0032] In one embodiment, the modification further comprises a detectable moiety (e.g., a reporter gene with or without its own promoter) and optionally a selectable marker at the Pint locus. In one embodiment, the detectable moiety and / or selectable marker are flanked upstream and downstream by site-specific recombination sites that direct removal of the detectable moiety and / or selectable marker. In one embodiment, the non-human animal further comprises an inducible site-specific recombinase that is compatible with the site-specific recombinase sites.
[0033] In one aspect, a non-human animal cell, tissue, or embryo is provided, wherein the cell or tissue expresses any one of HOTAIR, HOTTIP, Hoxa11os (formerly named HoxAllas), Pantr1 (formerly named lincRNA-Brn1-a), Pantr2 (formerly named lincRNA-Brn1-b), Ptgs2os2 (formerly named lincRNA-Cox2), Eldr (formerly named Fabl and lincRNA-Egfr), Lincenc1 (formerly named lincRNA-Enc1), Mannr (formerly named lincRNA-Evi1), Fendrr (formerly named lincRNA-Foxf1), Halr1 (formerly named Haunt and and a nucleic acid sequence encoding a functional lincRNA selected from the group consisting of lincRNA-HoxA1), Haglr (formerly named lincRNA-HoxD3), Celrr (formerly named Celr and lincRNA-Insig2), Crnde (formerly named lincRNA-Irx5), Kantr (formerly named Spasm and lincRNA-Jarid1c), Pint (formerly named linc-Pint and lincRNA-Mkln1), Trp53cor1 (formerly named lincRNA-p21), lincppara (formerly named lincRNA-Ppara), Peril (formerly named lincRNA-Sox2), Tug1 (formerly named lincRNA-Tug1), and combinations thereof.
[0034] In one embodiment, a cell or tissue that lacks a nucleic acid sequence encoding a functional lincRNA lacks a functional Pint (formerly known as lincRNA-Mlkn1).
[0035] In one embodiment, a nucleic acid construct is provided, comprising an upstream homology arm and a downstream homology arm, wherein the upstream and downstream homology arms target a lncRNA locus, wherein the construct can disrupt the transcription of the lncRNA, knock out the lncRNA, or replace the lncRNA.
[0036] In various aspects and embodiments, a targeting construct targeting a lncRNA locus comprises a sequence selected from a Kozak sequence, a sequence encoding a detectable moiety (e.g., a reporter, such as a reporter described herein, e.g., optionally operably linked to a promoter), a nucleic acid sequence encoding a selectable marker (e.g., optionally having a promoter operably linked thereto), and combinations thereof. In one embodiment, the reporter and / or the selectable marker are flanked by site-specific recombination sites arranged to effect deletion of the nucleic acid sequence encoding the selectable marker gene and / or the nucleic acid sequence encoding the detectable moiety. In one embodiment, the construct does not comprise a promoter operably linked to the detectable moiety.
[0037] In one embodiment, a method of disrupting an lncRNA is provided, comprising inserting a nucleic acid sequence into an lncRNA locus, where the insertion disrupts transcription of the lncRNA, removes one or more lncRNA coding regions, or removes the entire coding sequence of the lncRNA.
[0038] In one aspect, a method of making a non-human animal comprising a disruption or knockout of a lncRNA is provided, comprising modifying the genome of the non-human animal such that the non-human animal no longer expresses a functional version of the lncRNA. In one embodiment, the method comprises using a targeting vector to disrupt the transcription of the lncRNA, to remove one or more lncRNA coding regions, or to remove the entire coding sequence of the lncRNA in the genome of the non-human animal.
[0039] In one aspect, a method for producing a non-human animal comprising a knockout of an lncRNA function is provided. The method includes modifying the genome of a pluripotent or totipotent non-human animal cell to disrupt the transcription of an IncRNA, to remove one or more exons, or to remove the entire coding sequence of the lncRNA in the genome of the cell, using the cell as a donor cell, introducing the donor cell into a host embryo to form a donor cell / host embryo complex, and gestation of the donor cell / host embryo complex in a suitable non-human animal under conditions suitable for gestation, and after gestation, offspring are obtained that comprise a knockout of the lncRNA. In one embodiment, the offspring are produced homozygous for the knockout of the lncRNA function.
[0040] In one aspect, a method for producing a non-human animal comprising a knockout of lncRNA function is provided. The method includes modifying the genome of a somatic or germline cell of a non-human animal cell to disrupt the transcription of the lncRNA, to remove one or more lncRNA coding regions, or to remove the entire coding sequence of the lncRNA in the genome of the cell, using the genome of the cell in an enucleated egg to form a modified egg, gestation in a suitable surrogate non-human animal under conditions suitable for gestation, and obtaining a non-human animal progeny comprising the lncRNA knockout. In one embodiment, the progeny is produced homozygous for the knockout of lncRNA function.
[0041] In one embodiment, a method of making a non-human animal comprising a genetic modification in at least one lncRNA locus is provided, the method comprising: (a) contacting a pluripotent cell with a targeting construct comprising an insert nucleic acid flanked by 5' and 3' homology arms, the targeting construct homologously recombining with a lncRNA locus in the genome of the cell to form a modified pluripotent cell; (b) introducing the modified pluripotent cell into a host embryo; and (c) allowing a surrogate mother to gestate the host embryo, the surrogate mother giving birth to an offspring comprising the modified lncRNA locus, the genetic modification resulting in a loss of function of at least one lncRNA.
[0042] In one embodiment, a method for modifying a lncRNA locus in a pluripotent cell is provided, comprising introducing into the pluripotent cell a targeting construct comprising an insert nucleic acid flanked by 5' and 3' homology arms capable of undergoing homologous recombination with a lncRNA locus in the genome of the cell, and identifying a modified pluripotent cell comprising a targeted genetic modification at the lncRNA locus, wherein the genetic modification results in a loss of function of the lncRNA function. In one embodiment, the pluripotent cells are human induced pluripotent cells (iPS).
[0043] In various aspects and embodiments, the modified cells include, for example, pluripotent cells, induced pluripotent cells, stem cells, embryonic stem cells, etc. In a specific embodiment, the cells are embryonic stem (ES) cells. In a specific embodiment, the ES cells are mouse or rat ES cells.
[0044] In various aspects and embodiments, the non-human animals include, for example, ovine, bovine, porcine, and murine species of animals. In a specific embodiment, the animal includes a murine species, such as a mouse or a rat.
[0045] As will be appreciated by those of skill in the art upon reading this disclosure, other and further aspects and embodiments are included. In certain embodiments, for example, the following are provided: (Item 1) 1. A non-human animal, comprising within its genome at least one modified long non-coding RNA (lncRNA) locus, wherein the at least one modified lncRNA locus comprises a loss-of-function mutation within a nucleic acid sequence encoding the lncRNA. (Item 2) The non-human animal of item 1, wherein the lncRNA is a long intergenic non-coding RNA (lincRNA). (Item 3) 3. The non-human animal of any one of items 1 or 2, wherein the loss-of-function mutation is characterized by the disruption or knockout of at least one lncRNA function. (Item 4) 4. The non-human animal of item 3, wherein the modified lncRNA locus comprises a deletion of one or more exons encoding the lncRNA or a portion thereof. (Item 5) The disruption or knockout is (a) a deletion of one or more exons within the lncRNA gene beginning within the second exon of the lncRNA locus; (b) a deletion of one or more exons within the lncRNA locus beginning within the first exon of the lncRNA locus; or (c) The non-human animal of item 4, comprising a deletion of the entire RNA-coding region of the lncRNA locus. (Item 6) The non-human animal of item 3, wherein the disruption or knockout comprises replacing the lncRNA locus or a portion thereof with an inserted nucleic acid. (Item 7) 7. The genetically modified non-human animal of item 6, wherein the insert nucleic acid comprises a first nucleotide sequence encoding a reporter. (Item 8) 8. The genetically modified non-human animal of claim 7, wherein the first nucleotide sequence is operably linked to a promoter that drives expression of the reporter. (Item 9) 8. The genetically modified non-human animal of claim 7, wherein the first nucleotide sequence encoding the reporter is located within a lncRNA locus operably linked to an endogenous lncRNA promoter, and the endogenous lncRNA promoter drives expression of the nucleotide sequence. (Item 10) The non-human animal of item 9, wherein expression of the nucleic acid sequence follows an expression pattern of an lncRNA. (Item 11) 8. The genetically modified non-human animal of item 7, wherein the first nucleotide sequence comprises a Kozak consensus sequence. (Item 12) The substitution is (a) replacing one or more exons within a lncRNA locus beginning within a second exon of the lncRNA locus with the insert nucleic acid; (b) replacing one or more exons within the lncRNA locus beginning within the first exon of the lncRNA locus with the insert nucleic acid; or (c) The non-human animal according to any one of items 6 to 11, comprising replacing the entire RNA coding region of the lncRNA locus with the insert nucleic acid. (Item 13) 13. The non-human animal of any one of items 6 to 12, wherein the reporter is any of β-galactosidase, green fluorescent protein (GFP), enhanced green fluorescent protein (eGFP), mPlum, mCherry, tdTomato, mStrawberry, J-Red, DsRed, mOrange, mKO, mCitrine, Venus, YPet, enhanced yellow fluorescent protein (EYFP), Emerald, CyPet, cyan fluorescent protein (CFP), Cerulean, T-Sapphire, luciferase, alkaline phosphatase, or a combination thereof. (Item 14) 14. The non-human animal according to any one of items 6 to 13, wherein the insert nucleic acid further comprises a second nucleic acid sequence encoding a selection marker, and the second nucleic acid sequence is operably linked to a promoter. (Item 15) Item 16. The non-human animal according to item 14, wherein the insert nucleic acid comprises site-specific recombination sites flanking a segment encoding a reporter and / or a segment encoding a selectable marker. 16. The non-human animal of any one of items 1 to 15, wherein the lncRNA comprises Pint, Celrr, Crnde, Eldr, Fendrr, Halr1, Hotair, HOTTIP, Hoxa11os, Pantr1, Pantr2, Ptgs2os2, lincenc1, Trp53cor1, lincppara, Mannr, Haglr, Peril, Kantr, Tug1, or a combination thereof. (Item 17) The non-human animal has the following phenotype: (a) Premature aging-associated phenotypes, (b) perinatal mortality, (c) defects in lung development; (d) morphological malformations of the tail and hind limbs; (e) loss of muscle mass in one or more tissues, or (f) The non-human animal according to any one of items 1 to 16, characterized in that it has one or more of any of (a) to (e) in combination thereof. (Item 18) the lncRNA is Pint, and the non-human animal is (a) A slower growth rate than the wild-type control; (b) muscle weakness, (c) fiber formation, (d) lower body fat content than wild-type controls; (e) Lower femoral bone mineral density and bone mass than wild-type controls; (f) Decreased muscle mass compared to wild-type controls; (g) Decreasing median life expectancy; (h) spinal curvature, (i) Organ atrophy, or (j) The non-human animal of item 1, characterized by a premature aging-associated phenotype comprising any combination thereof of (a) to (i). (Item 19) 16. The non-human animal according to any one of items 1 to 15, wherein said non-human animal exhibits defects in brain development. (Item 20) 20. The non-human animal of item 19, wherein the lncRNA is Pantr2, Kantr, Peril, Celrr, Pantr1, Crnde, lincenc1, Pint, lincppara, or Tug1. (Item 21) 21. The genetically modified non-human animal according to any one of items 1 to 20, wherein the non-human animal is a mammal. (Item 22) 22. The genetically modified non-human animal of item 21, wherein the mammal is a rodent. (Item 23) 23. The genetically modified non-human animal of item 22, wherein the mammal is a mouse, a rat, or a hamster. (Item 24) A cell, tissue, or embryo derived from the non-human animal according to any one of items 1 to 23. (Item 25) A targeting vector comprising an insert nucleic acid flanked by 5' and 3' homology arms capable of homologous recombination with a lncRNA locus of interest. (Item 26) 26. The targeting vector of item 25, wherein the insert nucleic acid comprises a first nucleic acid sequence encoding a reporter. (Item 27) 27. The targeting vector of claim 26, wherein the first nucleic acid sequence encoding the reporter is operably linked to an endogenous promoter that drives expression of a lncRNA at the lncRNA locus following homologous recombination with the lncRNA locus of interest. (Item 28) 28. The targeting vector according to any one of items 26 to 27, wherein the reporter is any one of β-galactosidase, green fluorescent protein (GFP), enhanced green fluorescent protein (eGFP), mPlum, mCherry, tdTomato, mStrawberry, J-Red, DsRed, mOrange, mKO, mCitrine, Venus, YPet, enhanced yellow fluorescent protein (EYFP), Emerald, CyPet, cyan fluorescent protein (CFP), Cerulean, T-Sapphire, luciferase, alkaline phosphatase, or a combination thereof. (Item 29) 29. The targeting vector construct according to any one of Items 25 to 28, wherein the insert nucleic acid further comprises a second nucleic acid sequence encoding a selectable marker, and the second nucleic acid is operably linked to a promoter. (Item 30) 30. The targeting vector of item 29, further comprising site-specific recombination sites flanking the segment encoding the reporter and / or the segment encoding the nucleic acid of the selectable marker. (Item 31) 31. The targeting vector according to any one of items 25 to 30, wherein the first nucleic acid sequence and / or the second nucleic acid sequence further comprises a Kozak consensus sequence. (Item 32) 32. The targeting vector according to any one of Items 25 to 31, wherein the insert nucleic acid further comprises a promoter that drives expression of the reporter. (Item 33) 1. A method for generating a non-human animal comprising a genetic modification in at least one lncRNA locus, comprising: (a) contacting a pluripotent cell with a target construct comprising an insert nucleic acid flanked by a 5' homology arm and a 3' homology arm, wherein the target construct undergoes homologous recombination with a lincRNA locus in the genome of the cell to form an engineered pluripotent cell; (b) introducing the modified pluripotent cells into a host embryo; and (c) gestating the host embryo in a surrogate mother, the surrogate mother giving birth to an offspring comprising the modified lncRNA locus; wherein the genetic modification results in a loss of function of the at least one lncRNA. (Item 34) 34. The method of claim 33, wherein the lncRNA is a lincRNA. (Item 35) 35. The method of any one of items 33 to 34, wherein the genetic modification comprises disruption or knockout of at least one lncRNA function. (Item 36) 36. The method of any one of items 33 to 35, wherein the lncRNA comprises Pint, Celrr, Crnde, Eldr, Fendrr, Halr1, Hotair, HOTTIP, Hoxa11os, Pantr1, Pantr2, Ptgs2os2, lincenc1, Trp53cor1, lincppara, Mannr, Haglr, Peril, Kantr, Tug1, or a combination thereof. (Item 37) 1. A method for modifying a lncRNA locus in a pluripotent cell, comprising: (a) introducing into a pluripotent cell a targeting construct comprising an insert nucleic acid flanked by 5' and 3' homology arms capable of undergoing homologous recombination with a lincRNA locus; and (b) identifying a modified pluripotent cell comprising a targeted genetic modification at the lncRNA locus; The method, wherein the genetic modification results in a loss of function of a lncRNA function. (Item 38) 38. The method of claim 37, wherein the pluripotent cells are human iPS cells. (Item 39) 38. The method of claim 37, wherein the pluripotent cells are mouse or rat embryonic stem (ES) cells. (Item 40) 40. The method of any one of items 37 to 39, wherein the lncRNA comprises Pint, Celrr, Crnde, Eldr, Fendrr, Halr1, Hotair, HOTTIP, Hoxa11os, Pantr1, Pantr2, Ptgs2os2, lincenc1, Trp53cor1, lincppara, Mannr, Haglr, Peril, Kantr, Tug1, or a combination thereof. [Brief description of the drawings]
[0046] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request or payment of the necessary fee.
[0047] [Figure 1] Figure 1 shows the strategy for targeted disruption of the Fendrr locus. A partial map of the wild-type mouse Fendrr locus, including exons 1-6, is shown. Upon homologous recombination, the targeted LTVEC replaced a total of 19.2 kb of genomic Fendrr sequence with a LacZ-neomycin resistance cassette introducing a Kozak sequence. Open boxes indicate non-coding exons. Red and green boxes on the Fendrr genomic locus and within the LacZ neomycin resistance cassette are homologous sequences used for targeting. [Figure 2A]Figure 2 shows spatial and temporal lacZ reporter gene expression in mid-gestation lincRNA-targeted mouse embryos. A, Heterozygous e12.5 embryos were fixed and stained for β-galactosidase, showing widespread expression of the introduced lacZ reporter gene in the developing brain and maxillofacial regions (e.g., Pantr1 and Pantr2, Celrr and Haglr, see also Figure 9), neural tube (Pantr2, Halr1 and lincppara), dorsal aorta (Celrr), heart (Celrr, Haglr, see also Figure 9), lung (Fendrr), limb buds (HOTTIP, Hoxa11os, and Mannr), foregut (HOTTIP, Hoxa11os, and Fendrr), dorsal and tail (HOTAIR, HOTTIP, and Hoxa11os). A similar analysis showed widespread lacZ expression patterns in Tug1. Meanwhile, expression of other reporter genes could be restricted to the epidermis (Eldr), mammary buds (Lincenc1, see also Figure 9), or whisker placode (Trp53cor1, see also Figure 9). The examples shown represent at least five genotype-confirmed embryos per one lincRNA knockout project. B, Expression patterns of selected lincRNAs (HOTTIP, Hoxa11os, and Celrr) from the indicated stages (e9.5–e12.5) began early at a restricted site of expression and spread beyond this initiation site at later stages. Celrr expression is restricted to the brain at e9.5 and progresses to the spinal cord by e12.5. Hoxa11os expression also begins in the developing tail bud and progresses to the entire tail region, hind limbs, and forelimbs of the embryo by e12.5. HOTTIP expression also begins in the tail during development and was observed in the developing free limbs of the forelimbs and hindlimbs by e11.5 and e12.5. Examples shown represent at least five genotype-confirmed embryos per lincRNA project. [Figure 2B]Figure 2 shows spatial and temporal lacZ reporter gene expression in mid-gestation lincRNA-targeted mouse embryos. A, Heterozygous e12.5 embryos were fixed and stained for β-galactosidase, showing widespread expression of the introduced lacZ reporter gene in the developing brain and maxillofacial regions (e.g., Pantr1 and Pantr2, Celrr and Haglr, see also Figure 9), neural tube (Pantr2, Halr1 and lincppara), dorsal aorta (Celrr), heart (Celrr, Haglr, see also Figure 9), lung (Fendrr), limb buds (HOTTIP, Hoxa11os, and Mannr), foregut (HOTTIP, Hoxa11os, and Fendrr), dorsal and tail (HOTAIR, HOTTIP, and Hoxa11os). A similar analysis showed widespread lacZ expression patterns in Tug1. Meanwhile, expression of other reporter genes could be restricted to the epidermis (Eldr), mammary buds (Lincenc1, see also Figure 9), or whisker placode (Trp53cor1, see also Figure 9). The examples shown represent at least five genotype-confirmed embryos per one lincRNA knockout project. B, Expression patterns of selected lincRNAs (HOTTIP, Hoxa11os, and Celrr) from the indicated stages (e9.5–e12.5) began early at a restricted site of expression and spread beyond this initiation site at later stages. Celrr expression is restricted to the brain at e9.5 and progresses to the spinal cord by e12.5. Hoxa11os expression also begins in the developing tail bud and progresses to the entire tail region, hind limbs, and forelimbs of the embryo by e12.5. HOTTIP expression also begins in the tail during development and was observed in the developing free limbs of the forelimbs and hindlimbs by e11.5 and e12.5. Examples shown represent at least five genotype-confirmed embryos per lincRNA project. [Diagram 3]Figure 3 shows LacZ reporter gene expression (blue) in the brains of 6- to 8-week-old lincRNA F0 generation heterozygotes. A, Celrr, widespread expression in gray matter except for the lateral cerebellum and base of the pons; B, Crnde, expression in the colliculus (dorsal view, arrows); C, Pantr1, expression in the neocortex, olfactory bulb, basal forebrain, and hypothalamus; D, Pantr2, expression in the neocortex, olfactory bulb, cerebellum, hypothalamus, and basal forebrain; E, Lincenc1, expression in multiple parts of the neocortex, cerebellum, and medial, with a particularly strong expression pattern in the olfactory projection and olfactory projection areas of the temporal cortex (ventral view, red arrows). Expression in the hypothalamus; F, Pint, ubiquitous expression in grey matter with particularly strong expression in the hypothalamus; G, lincppara, widespread expression in grey matter with particularly dense expression in the hypothalamus; H, Peril, expression at the midline of the hypothalamus (ventral view, arrowhead); I, Kantr, potentially some expression in deep cerebellar layers; (ventral view, asterisk); and J, Tug1, spinal grey matter expression and light grey matter expression in most structures except the neocortex. n=2 genotyped male mice per lincRNA knockout project. [Figure 4] FIG. 4 shows that Pint shows increased expression from postnatal day 3 to week 8 of age. LacZ reporter gene expression (blue) in F0 heterozygotes at day 3, week 3, and week 8 shows that Pint expression increases with age. A, At day 3, β-galactosidase staining is observed only in the brain, tendons and ligaments of the hind limbs, and in parts of some bronchioles (arrows) of the lungs. B, At week 3, there is increased staining in the brain, hind limbs, atria of the heart, lungs, and liver. C, By week 8 of age, the whole brain, skeletal muscle of the hind limbs and chest, atria and myocardium, lungs, and liver tissue all show strong β-galactosidase staining indicative of increased Pint expression. Examples shown represent n>4 mice per group. [Diagram 5]Figure 5 shows premature aging-associated phenotypes in Pint knockout mice. (A) Pint- / - and Pint+ / - male mice show significantly slower growth rates than their wild-type (WT) littermates and begin to show significant weight loss around 6 months of age. Data are plotted as mean + / - SEM, n>9 mice per group. Significance was assessed by one-way ANOVA (*, P<0.05; **, P<0.005; ***, P<0.001). (B) Kaplan-Meier analysis of homozygous versus heterozygous and WT mice. Pint- / - male mice show significantly reduced survival compared to Pint+ / - and WT littermates. Data are plotted as percentage survival over one year of observation. (C) Ventral and dorsal skin sections of Pint- / - mice compared to Pint+ / - and WT littermates. (D, E, F, and G) Micro-CT assessment of body composition at 12, 26, and 52 weeks of age. (D, E) Male Pint- / - and Pint+ / - mice show a significant reduction in body fat as early as 26 weeks of age. Female Pint- / - mice have significantly less body fat at older ages, at 52 weeks of age (***, P<0.001, one-way ANOVA). (F, G) Significant reductions in femoral bone mineral density (BMD) were observed in male and female Pint- / - compared to Pint+ / - and WT littermates (*, P<0.05; ***, P<0.001, one-way ANOVA). (H) Micro-CT images show a pronounced vertebral curvature (curvature of the spine) seen in older male or female Pint+ / - mice compared to WT littermates. (I) Approximately 70% of male or female Pint- / - mice have spinal curvature by 12 weeks of age, compared to 0-20% of Pint+ / - and WT littermates. By 26 weeks of age, the percentage of Pint- / - mice with spinal curvature increased to nearly 90%, appearing in approximately 60% of Pint- / - mice, compared to less than 20% of WT littermates. n>9 mice per group for all observations reported. [Figure 6]Figure 6 shows Fendrr knockouts exhibiting abnormal lung morphology at e13.5. A. LacZ reporter gene expression in Fendrr KO embryos at e12.5 shows positive expression in the frontonasal region (FN) of the face, the aorta-gonad-mesonephoros (AGM) region, and the airways including the lungs (L) and trachea (T). B. Dissection of lungs at e13.5 revealed abnormal and disorganized globular phenotypes in the cerebral lobes of KO compared to Het. [Figure 7] Figure 7 shows homeotic transformation observed in the fourth caudal vertebra of HOTAIR KO mice. A. Visualization of the sacral and tail regions of the mouse skeleton by μCT reveals homeotic transformation of the fourth caudal vertebra in HOTAIR KO mice into a structure similar to that of the third caudal vertebra. B. Comparison of the dorsal, lateral, and ventral sides of the fourth caudal vertebra in WT and HOTAIR KO reveals structural abnormalities in the KO indicative of homeotic transformation. [Figure 8]FIG. 8 shows that HOTTIP KO mice exhibited abnormal hindlimb posture, reduced forelimb and hindlimb grip strength, and a muscle wasting phenotype. A. HOTTIP KO mice exhibited an abnormal "clasping" posture of the hindlimbs upon tail suspension. WT, wild type; KO, knockout. B. Cage endurance test revealed that HOTTIP KO mice had a reduced ability to remain suspended from the top of an inverted wire cage. n=5 mice per group. C. Left and right TA (tibialis anterior), GA (gastrocnemius), and Quad (quadriceps) muscles were harvested and weighed from WT, Het, and KO mice. Mouse weights were normalized to body weight and calculated to include both right / left muscle weights. Data are mean ± SEM, n=6 mice per group. A significant increase in muscle weight was observed only in the GA of HOTTIP KO animals in both males and females (male data not shown). Asterisks indicate significant differences in KO GA muscle weight compared to all other control groups (P<0.01). D. Comparison of GA muscle fibers in WT, Het, and KO. A significant reduction in fiber content was observed in KO. Significant differences were assessed using one-way ANOVA (P<0.001). E. Comparison of mean cross-sectional area of muscle fibers. Sections taken from GA muscles were stained with an antibody against laminin (Sigma) and measured. There is no noticeable size difference between KO and control skeletal muscles. n=6 mice per group for all muscle analyses. [Figure 9]Figure 9 shows precise staining in subregions of four lincRNA knockouts that show highly specific staining patterns, namely Peril, Ptgs2os2, Trp53cor1, and Lincenc1, and the specific midgestation lacZ expression profile. (A) LacZ reporter profiling of Peril shows a specific neural expression pattern as well as strong expression in the heart and posterior tail regions. (B) Ptgs2os2 lacZ reporter expression is restricted to the base of the developing forelimbs and hindlimbs. (c) Trp53cor1 lacZ reporter expression is specific to the developing whisker placode in the nasal process. E12.5 embryos collected from the same litter briefly capture the progression of whisker placode development. (D) Forelimbs and hindlimbs of Lincenc1+ / - embryos were removed to expose mammary bud expression (arrowheads). Ventral view of E12.5 Lincenc1+ / - embryos: lacZ expression is detected in five pairs of mammary buds. [Figure 10] Figure 10 shows a phenotype characterized by loss of the calcaneus in HOTTIP knockouts. Skeletal malformations observed in HOTTIP mutant mice. In addition to the hindlimb skeletal muscle phenotype, HOTTIP- / - mice also display skeletal bone abnormalities visualized by 3D micro-CT. Both female and male (C and F) HOTTIP- / - mice have shortened calcaneus (arrows) compared to WT (in A and D) and HOTTIP- / - littermate controls (in B and E). [Figure 11] Figure 11 shows a table of reporter expression in embryos and living tissues of lncRNA knockouts in this study (Table 2). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0048] Detailed Description of the Invention Vocabulary Description The term "embryonic stem cell" or "ES cell" includes embryo-derived totipotent or pluripotent cells that, upon introduction into an embryo, are capable of contributing to any tissue of the developing embryo. The term "pluripotent cell" includes undifferentiated cells that retain the ability to develop into multiple differentiated cell types.
[0049] The term "large targeting vector" or "LTVEC" includes large targeting vectors for eukaryotic cells that are derived from fragments of cloned genomic DNA that are typically used in other approaches that are intended to carry out homologous gene targeting in eukaryotic cells. Examples of LTVEC include, but are not limited to, bacterial homologous chromosomes (BAC) and yeast artificial chromosomes (YAC).
[0050] The term "recombination site" includes a nucleotide sequence that is recognized by a site-specific recombinase and can serve as a substrate for recombination to occur.
[0051] The term "site-specific recombinase" includes a group of enzymes that promote recombination between "recombination sites." Examples of site-specific recombinases include, but are not limited to, Cre, Flp, and Dre recombinases.
[0052] The term "germline" in reference to a nucleic acid sequence includes a nucleic acid sequence that can be passed on to offspring.
[0053] The phrase "operably linked" means that components are linked to function together in the intended manner. In one example, a nucleic acid sequence encoding a protein may be operably linked to regulatory sequences (e.g., promoters, enhancers, silencer sequences, etc.) to maintain proper transcriptional control.
[0054] As used herein, the term "long non-coding RNA" or "lncRNA" includes non-protein-coding transcripts greater than 200 nucleotides in length.
[0055] As used herein, the term "long intergenic non-coding RNA" or "lincRNA" includes a subgroup of lncRNAs. As used herein, lincRNAs do not overlap with exons of protein-coding regions of the genome.
[0056] The term "locus" is defined as a segment of DNA within genomic DNA. For example, a lncRNA locus is a DNA segment within genomic DNA that encodes a lncRNA.
[0057] I. Compositions Comprising Genetic Modifications of at Least One lncRNA Locus Non-human animals, cells, tissues, and embryos are provided that contain lncRNA loss of function, including but not limited to, disruption or knockout of one or more lncRNAs. Methods and methods for manipulating lncRNA expression are provided. Targeting compositions for modifying or knocking out lncRNAs are also provided. Non-human animals, cells, and tissues that exhibit phenotypes associated with non-function of one or more lncRNAs are provided. Although the following description relates to the investigation of certain lncRNAs, the methods and compositions can be performed with any lncRNA.
[0058] Provided herein are non-human animals, cells, tissues and embryos that comprise targeted genetic modification in at least one long non-coding RNA (lncRNA) locus.In such cases, the modified lncRNA locus comprises loss-of-function mutation in the nucleic acid sequence that encodes the lncRNA.Also provided are cells, tissues and embryos derived from non-human animals that comprise loss-of-function mutation in at least one lncRNA.
[0059] The term "loss of function" as it relates to a lncRNA can include any modification to a lncRNA locus that results in a reduced or absent expression of the lncRNA and / or a reduced or absent activity / function of the lncRNA. The expression level of a lncRNA can be measured directly, for example, by assaying the level of the lncRNA in a cell or organism.
[0060] In general, the expression level and / or activity of a lncRNA is decreased when the expression level and / or activity level of the lncRNA is statistically lower (p≦0.05) than the lncRNA level in a suitable control cell or organism that has not been genetically modified or mutagenized to inhibit the expression and / or activity of the lncRNA. In specific embodiments, the concentration and / or activity of the lncRNA is decreased by at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% or more compared to a control cell or organism that has not been modified to decrease the level and / or activity of the lncRNA.
[0061] In other examples, cells or organisms with targeted genetic modifications that reduce the expression and / or activity levels of lncRNAs are selected using methods such as, but not limited to, Southern blot analysis, DNA sequencing, PCR analysis, or phenotypic analysis, and such cells or organisms are then used in the various methods and compositions described herein.
[0062] A "subject cell" or a "subject organism" is a cell / tissue resulting from a genetic mutation (e.g., a genetic modification disclosed herein) or a descendant of a cell / tissue so modified and containing such a mutation. A "control" or "control cell" or "control organism" provides a reference point for measuring phenotypic changes in a subject cell or organism. In one embodiment, the control cell / organism is as closely matched as possible to the cell / organism having the genetic modification in the lncRNA (e.g., each cell may be derived from the same cell lineage), except that the control cell / organism lacks the genetic modification or mutation that results in reduced expression and / or activity. In other examples, the control cell / organism may include, for example, (a) a wild-type cell / tissue, i.e., a wild-type cell / tissue that is of the same genotype as the starting material for the genetic mutation that gave rise to the control cell / organism; (b) a cell / organism of the same genotype as the starting material, but that has been genetically modified with a null construct (i.e., with a construct that has no known effect on the trait of interest, such as a construct that includes a marker gene); (c) a cell / organism that is a non-genetically modified descendant of the subject cell / organism (i.e., the subject cell / organism is from the same cell lineage); (d) a cell / organism that is genetically identical to the subject cell / organism, but that is not exposed to a condition or stimuli that induces expression of the gene of interest; or (e) the subject cell / organism itself, in which the genetic modification does not result in an alteration in the expression of the polynucleotide of interest.
[0063] The term "animal" in reference to an animal, cell, tissue, or embryo includes mammals, fish, and birds. Mammals include, for example, humans, non-human primates, monkeys, apes, cats, dogs, horses, stud cattle, deer, bison, sheep, rodents (e.g., mice, rats, hamsters, guinea pigs), livestock (e.g., bovine species such as dairy cows, steers, etc., ovine species such as sheep, goats, and porcine species such as pigs and wild boars. Birds include, for example, chickens, turkeys, ostriches, geese, ducks, and the like. Domesticated animals and farm animals are also included. The phrase "non-human animals" referring to an animal, cell, tissue, or embryo excludes humans.
[0064] In one embodiment, the animal is a non-human animal. In another embodiment, the human animal is a mammal. In another embodiment, the mammal is a rodent. In yet another embodiment, the rodent is a mouse, a rat, or a hamster.
[0065] The genetic modifications described herein may include one or more deletions from the lncRNA locus of interest, additions from the lncRNA locus of interest, replacements of the lncRNA locus of interest, and / or any combination thereof. The locus of interest may include coding regions or non-coding regulatory regions.
[0066] The genetic modifications provided herein are targeted to a lncRNA locus of interest. The loss of function of lncRNA can result from targeted genetic modification in lncRNA gene (i.e., genetic modification in regulatory region, coding region, exon, and / or intron, etc.). Such targeted modification includes, but is not limited to, addition of one or more nucleotides, deletion of one or more nucleotides, substitution of one or more nucleotides, disruption of lncRNA locus, knockout of lncRNA locus or a part thereof, knock-in of lncRNA locus or a part thereof, replacement of endogenous lncRNA nucleic acid sequence or a part thereof with heterologous nucleic acid sequence, or combinations thereof. In specific embodiments, at least 1, 2, 3, 4, 5, 7, 8, 9, 10, 50, 100, 400 or more nucleotides are changed to form targeted genome modification.
[0067] In one embodiment, the loss-of-function mutation is characterized by the disruption or knockout of at least one lncRNA function.
[0068] The lncRNA locus can be genetically modified in any region of the locus, such that the modification results in the loss of function of the lncRNA.In one embodiment, the modification of the lncRNA locus comprises the deletion of the entire lncRNA coding region or a part thereof.In one embodiment, the modified lncRNA locus comprises the deletion of one or more exons that code for the lncRNA or a part thereof.In another embodiment, the deletion comprises the deletion of one or more exons in the lncRNA locus, the deletion starting from the first exon of the lncRNA locus.In another embodiment, the deletion comprises the deletion of one or more exons in the lncRNA locus, the deletion starting from the second exon of the lncRNA locus.
[0069] In some cases, the lncRNA locus or a portion thereof is replaced with the insert nucleic acid. In such cases, the replacement can be the replacement of the entire RNA coding region of the lncRNA locus or a portion thereof with the insert nucleic acid, the replacement of one or more exons of the lncRNA locus with the insert nucleic acid, the replacement of one or more exons in the lncRNA locus starting from the first exon of the lncRNA locus with the insert nucleic acid, or the replacement of one or more exons in the lncRNA locus starting from the second exon of the lncRNA locus with the insert nucleic acid.
[0070] In some cases, the insert nucleic acid is placed into the lnRNA locus such that the insert nucleic acid is operably linked to the endogenous lncRNA promoter such that the endogenous lncRNA promoter drives expression of the insert nucleic acid. In such cases, expression of the nucleic acid sequence follows the expression pattern of the lncRNA.
[0071] In one embodiment, the lncRNA locus or a part thereof is replaced with an insert nucleic acid comprising a first nucleic acid sequence encoding a reporter. For example, when the insert nucleic acid is placed in the lncRNA locus that comprises a reporter gene and is operably linked to a lncRNA promoter, the expression of the reporter gene is driven by the endogenous lncRNA promoter. Alternatively, the insert nucleic acid is not inserted in a state that is operably linked to the endogenous lncRNA promoter. In such a case, the insert nucleic acid may comprise a promoter. In one embodiment, the insert nucleic acid comprises a reporter gene operably linked to a promoter gene that drives the expression of the reporter.
[0072] In one embodiment, the lncRNA locus or a portion thereof is replaced with an insert nucleic acid comprising a second nucleic acid sequence encoding a selectable marker. In such a case, the second nucleic acid sequence is operably linked to a promoter that drives expression of the selectable marker.
[0073] In another embodiment, the lncRNA locus or a portion thereof is replaced with an insert nucleic acid comprising a reporter gene and a selectable marker gene. In such cases, the reporter gene and / or the selectable marker gene may or may not be operably linked to a promoter.
[0074] A variety of promoters that can be used in the methods and compositions are provided elsewhere herein.
[0075] Such genetic modifications (including genetic modifications that result in the reduction or modulation of expression and / or activity of the target lncRNA) can also be transmitted through the germline. In a specific embodiment, the genetic modification results in the knockout of the desired target locus. The use of such non-human animals can be found, for example, in various experimental methods discussed elsewhere herein.
[0076] For example, lncRNA knockouts provide animal models to study IncRNA function, the role of lncRNA in development, and the role of lncRNA in various cellular pathways and diseases (including, but not limited to, aging, such as premature aging, brain development, embryonic development, lung development, bone development, muscle development, cancer, or transcription).
[0077] A variety of methods can be used to generate targeted gene modifications and are described elsewhere herein.
[0078] A. lncRNA The non-human animals, cells, tissues, and embryos used in the methods and compositions provided herein have a genetic modification that results in a loss of function of at least one lncRNA. lncRNAs are long non-coding RNAs longer than 200 nucleotides. A subgroup of lncRNAs, long intergenic non-coding RNAs (lincRNAs), are intergenic and do not overlap with protein-coding regions.
[0079] Any lncRNA locus can be modified with the methods and compositions provided herein. In one embodiment, the genetically modified non-human animal, cell, tissue, or embryo comprises a genetic modification of a lncRNA. In another embodiment, the lncRNA is a lincRNA.
[0080] Non-limiting examples of lncRNAs include HOTAIR, HOTTIP, Hoxa11os (formerly known as HoxA11as), Pantr1 (formerly known as lincRNA-Brn1-a), Pantr2 (formerly known as lincRNA-Brn1-b), Ptgs2os2 (formerly known as lincRNA-Cox2), Eldr (formerly known as Fabl and lincRNA-Egfr), Lincenc1 (formerly known as lincRNA-Enc1), Mannr (formerly known as lincRNA-Evi1), Fendrr (formerly known as lincRNA-Foxf1), Halr1 (formerly known as HAunt and lincRNA-HoxA1), Ha glr (formerly known as Mdgt and lincRNA-HoxD3), Celrr (formerly known as Celr and lincRNA-Insig2), Crnde (formerly known as lincRNA-Irx5), Kantr (formerly known as Spasm and lincRNA-Jarid1c), Pint (formerly known as linc-Pint and lincRNA-Mlln1), Trp53cor1 (formerly known as lincRNA-p21), lincppara (formerly known as lincRNA-Ppara), Peril (formerly known as licRNA-Sox2), Tug1 (formerly known as lincRNA-Tug1), or any combination thereof.
[0081] It is now clear that protein-coding genes are not all that exist in the genome (Mattick, JS (2009), PLoS Genet 5:21000459). Large-scale genome-wide expression studies in mammalian cells have revealed that approximately 3 / 4 of the genome can be expressed as RNA (Carninci, P. et al. (2005), Science 309:1559-1563; Dkena;o, S. et al. (2012), Nature 489:101-108; Kapranovf, P et al. (2007), Science 316:1418-1488) and that the vast majority of transcripts do not code for proteins. Notably, non-coding transcripts are a diverse class known as long non-coding RNAs (lncRNAs). Approximately 15,000 transcripts from approximately 10,000 genomic loci in human cells have been described (Derrien, T. et al. (2012) Genome Res 22:1775-1789), and lncRNAs and a subclass known as long intergenic noncoding (lincRNAs) (Guttman, M. et al. (2009) Nature 458:223-227; Khalil et al. (2009)) are similar in their gene structure, synthesis, and chromatin properties. Whether this structural similarity extends to functional diversity in matching proteins remains an open question.
[0082] Studies of the function of individual lncRNAs have been reported in a variety of areas, including X-chromosome inactivation (Marahrens, Y. et al., (1997), Genes Dev 11:156-166), imprinting (Leighton, PA et al., (1995), Nature 375:34-39; Mohammad, F. et al., (2010), Development 137: 2493-2499; Sleutels, F. et al. (2002), Nature 415:810-813; Rakahashi, N. et al. (2009), Hum Mol Genet 18:1879-1888), retinal differentiation (Young, TL et al. (2005), Curr Biol 15:501-512), and heart and body wall differentiation (Grote, P. et al. (2013), Dev Cell 24:206-214). Studies on the lincRNA HOTAIR first revealed that lincRNAs can regulate gene expression at sites distant from the lincRNA's own site by inducing chromatin modifying complexes (in the case of HOTAIR, polycomb repressive complex 2) to specify genomic loci (Rinn, JL et al. (2007), Cell 129:1311-1323). Similar mechanisms of action were found for Xist lncRNA in X-chromosome inactivation (Zhao, J. et al., (2008), Science 322:750-756) and AIR and Kcnq1ot1 lncRNA in imprinting. These findings suggest an even broader role for lncRNAs in gene expression, which was supported by the analysis of correlated protein expression patterns of lincRNAs and protein-coding genes pointing to the involvement of lincRNAs in a wide range of cellular processes and organ system physiology (Guttman et al., (2009)). Many recent studies on lncRNAs employ global genomic strategies that have established a complete picture of the role of lncRNAs as a class. To answer questions about whether the effects of lncRNAs on protein gene expression are widespread, elusive, and buffering, or specific, direct, and limited, it is necessary to examine the role of each lncRNA in living animals.
[0083] In the following description, the present specification provides non-limiting examples of genetic modifications that result in knocking out various lncRNAs in mouse knockout models.Knockout of 20 lincRNA genes was performed to investigate gene expression and phenotype in mice.This investigation included LacZ profiling that showed diverse spatiotemporal patterns of tissue-specific expression, and revealed two knockout lines that showed perinatal lethality, and further revealed other phenotypes, including premature aging-related phenotypes, and defects in lung, skeleton, brain, and muscle.
[0084] To begin to address lncRNA function in living animals, we generated knockout mouse lines for 20 lincRNA genes. Each mutant allele carried a lacZ reporter whose expression profiling revealed broad spatiotemporal and tissue-specific transcription patterns in adults and embryos. Among approximately 18 homozygous knockout lines, six (approximately 33%) had identifiable mutant phenotypes, two of which (11%) were perinatal lethal, including premature aging-associated phenotypes, morphological abnormalities in the brain, lung, skeleton, and muscle, and widespread changes in gene expression patterns, together indicating diverse roles for this new class of functional RNAs in embryonic development and in a wide variety of tissues and organs.
[0085] B. Genetic Modification of lncRNA Loci Provided herein are methods and compositions for genetic modification of at least one lncRNA locus in a non-human animal, cell, tissue, or embryo.
[0086] The genetic modification of the lncRNA locus of interest can be any modification of the locus described elsewhere herein (i.e., deletion, insertion, substitution, etc.). In such cases, the genetic modification results in a loss of function of the lncRNA. In one embodiment, the genetic modification comprises the disruption or knockout of at least one lncRNA.
[0087] i. Knockout allele design and construction Design and construction of modified lncRNA alleles, such as knockouts, are complicated by several technical problems. For example, there is generally no structural-functional correlation between multiple lncRNAs, and furthermore, lncRNA loci do not have open reading frames. Therefore, the same strategies that guide the design of alleles for modifying protein-coding sequences (e.g., knockouts) may not be applicable to lncRNAs. In addition, the boundaries between lncRNA genes are not well defined, which further complicates the design of modified lncRNA alleles, such as knockouts. Non-limiting examples of these technical difficulties in lncRNA knockout design and the strategies used herein to successfully overcome these hurdles are described in detail herein below.
[0088] In one example, the methods and compositions provided herein are applied to mice as a model system.However, although the following description is about mice, any non-animal, cell, tissue or embryo can be used with the methods and compositions described herein.
[0089] Since its invention nearly 25 years ago, methods for generating genetically modified (so-called knockout) mice have established the mouse as the premier system for studying mammalian gene function (Capecchi, MR (2001), Nat Med 7:1086-1090; Evans, MJ (2001), Nat Med 7:1081-1083; Smithies, O. (2001), Natmed 7:1083-1086)). With few exceptions, the application of knockout mouse technology to both individual genetic studies and large-scale international projects (Bradley, A. et al. (2012) Mamm Gemnome 23:580-586) has focused on protein-coding genes, although current attempts to create a universal knockout mouse resource for microRNAs (Prosser, HM et al. (2011) Nat Biotechnol 29:840-845) (mcmanuslab.ucsf.edu / microrna_knockout) demonstrates the value of applying the technology to non-coding RNA.
[0090] However, applying knockout mouse technology to lncRNAs raises several technical problems and difficulties. Most proteins have elements or domains that are known or at least predicted to be important for function. Removing the coding sequence for these essential parts is often sufficient to create a null allele. Similarly, conditional alleles can be designed, isolating an important exon or exons for subsequent deletion by the action of tissue-specific recombinases. Because structure-function relationships have been established for a few but not yet all lncRNAs, and because of the lack of open reading frames as a guide, knockout strategies useful for protein-coding genes may not be applicable to genomic loci that code for lncRNAs. Although annotation of lncRNA genes has improved (Derrien et al., (2012)), the exact boundaries of some of these genes may still be unclear, which may complicate knockout allele design. A powerful tool that has been applied to knockout mice for protein-coding genes is to replace the target gene with a reporter (such as the coding sequence for β-galactosidase or a fluorescent protein) whose expression is controlled by the promoter of the target gene, thereby reporting the spatial and temporal pattern of expression in the mouse. Non-limiting examples of reporter genes are provided elsewhere herein.
[0091] Reporter gene replacement was performed at the well-studied Gt(ROSA)26Sor locus, which encodes a lncRNA (Zambrowicz, BP et al., (1997) Proc. Natl Acad Sci USA 94:3789-3794) and the small non-coding RNA miR-155 (Thai, TH et al., (2007), Sciein ce 316:604-608). However, it appears necessary to develop rules for creating such alleles of lncRNAs. Despite these qualifications, with thousands of identified lncRNAs, the time is ripe to explore the application of the power of knockout mouse technology to this new class of genes. With this goal in mind, described herein is the creation of knockout mouse lines for 20 lincRNAs, each line carrying a gene ablation deletion allele, for example by β-galactosidase replacement.
[0092] Any lncRNA locus can be modified by the methods and compositions provided herein.In one embodiment, the lncRNA is a long intergenic non-coding RNA (lincRNA).Non-limiting examples of lincRNA genes are listed in Table 1.However, the methods and compositions applied herein can be performed on any lncRNA.
[0093] Table 1 lists the 20 lincRNAs on 10 different chromosomes targeted in this study and the 26 knockout deletion alleles created. We selected members of the long intergenic noncoding RNA class for mutation because, by definition, multiple lincRNA genes are isolated from adjacent protein-coding genes and their transcripts do not overlap (Guttman et al., (2009)). This feature allowed the design of deletion alleles that have at least the potential to be interfered with by the expression of adjacent genes. With an emphasis on neural expression and because of their potential involvement in development and regulation of gene expression, the target lincRNA genes were selected to reflect a variety of expression patterns (Cabili, MN et al., (2011), Genes Dev 25:1915-1927; Khalil, AM et al., (2009), Proc Natl Acad Sci USA 106:11667-11672). [Table 1-1] [Table 1-2]
[0094] The design strategy for lincRNA knockout mutations was guided by two objectives. First, we created alleles that actually report on the transcriptional activity of the lincRNA gene. Despite the mounting evidence for tissue-specific lincRNA expression (Cabili et al., (2011)), it was desirable to complement this knowledge base by generating fine-grained expression patterns afforded by lacZ expression profiling, which allows spatially and temporally resolving tissue and organ expression, revealing subdomains and, in some cases, cell type characteristics not resolved by tissue dissection experiments. In addition, none of the published lincRNA knockout alleles incorporated a reporter. Second, we created gene ablation deletions that abolished lincRNA synthesis and function in such a way that any phenotypes associated with the mutations would be informative about the critical function of the target RNA. The knockout deletions ranged in size from approximately 400 bp to 50 kb, and half were missing all of the annotated exons. In most of the remaining alleles, the deletion started in the second exon. The application of VelociGene® genetic engineering methods (Valenzuela, DM et al., (2003a), Nat Biotechnol 21:652-659) to the construction and use of large targeting vectors based on bacterial artificial chromosomes (LTVEC) was key in enabling the construction of the large gene ablation deletions required to ensure null alleles of this new class of high molecular weight functional RNAs.
[0095] Little is known about the interrelationship between the structure and function of the lincNA gene that can guide allele design. Experiments with disruption of the Gt(ROSA)26Sor (Zambrowicz et al., (1997)) and BIC (miR-155) (Thai et al., (2007)) genes have demonstrated that deletions and insertions after the first exon can result in reliable tissue-specific expression of β-galactosidase or other reporters. However, this strategy may fail to achieve a complete null mutation if the fusion transcript derived from the modified allele retains the functional portion of the lincRNA from the 5' portion encoded in the first exon (Tsai, MC et al., (2010), Science 329, 689-693). Thus, the knockout allele designs shown in Table 1 were a compromise between the desire for a complete ablation mutation with the highest probability of disrupting lincRNA function and the goal of creating alleles that produced accurate and informative gene expression profiles from the β-galactosidase receptor. For example, for the HOTAIR gene, two alleles were created, one lacking near the entire RNA coding sequence and the other with a deletion beginning in the second exon. Both alleles produced identical phenotypes (see below), but only the second acted as a reporter of gene expression.
[0096] For lincRNAs that are in close proximity to protein-coding genes and may share divergent promoters, the deletion start point was placed within the second exon to avoid possible disruption of transcription of the neighboring gene. Figure 1 shows one such example for the Fendrr (lincRNA-Foxf1) gene. The diagram shows an example of design elements common to all alleles: targeted deletion of all or most of the lincRNA coding sequence, as well as a cassette containing sequences of the E. coli lacZ gene encoding β-galactosidase and a cassette expressing neomycin phosphotransferase (neomycin phosphotransferase) for selection of G418-resistant ES cell colonies. r) and a substitution of . The drug selection cassette is flanked by LoxP recombinase recognition sites that allow Cre-mediated excision prior to phenotypic analysis. Since there is no functional open reading frame to fuse the LacZ sequence to, each allele may have an initiation codon and a Kozak consensus sequence (Kozak, M (1987), Nucleic Acid Res 15, 8125-8148) for efficient translation of the β-galactosidase reporter. Non-limiting examples of Kozak consensus sequences are A / GCCRCCATGG (SEQ ID NO: 1) and GCCGCCRCCATGG (SEQ ID NO: 2), where R is A or G.
[0097] The LTVEC targeting vector was introduced into ES cells and correctly targeted clones were screened by the loss-of-allele method (Frendewey, D. et al., (2010), Methods Enzymol 476, 295-307).
[0098] VelociMouse® method (Poueymirou, wT et al., 2007), Nat Biotechnol 25, 91-99) for injection into 8-cell embryos The method was applied and the targeted ES cells were introduced into F0 generation heterozygous mice derived entirely from the ES cells, ready for lacZ expression profiling or breeding to homozygosity. Further details of the methods for generating lncRNA knockout animals are provided in Examples 1-13 provided elsewhere herein.
[0099] ii. Reporter expression profiling As described elsewhere herein, genetic modification of lncRNA locus may include replacing or inserting / adding an insert nucleic acid into lncRNA locus or a part thereof. In some cases, the insert nucleic acid includes a reporter gene. In one embodiment, the reporter gene is placed in the lncRNA locus operably linked to the endogenous lncRNA promoter. Such modification allows the reporter gene to be expressed by the endogenous lncRNA promoter. Alternatively, the reporter gene is not placed in operably linked to the endogenous lncRNA promoter.
[0100] Any reporter (or detectable moiety) can be used in the methods and compositions provided herein.Non-limiting examples of reporters include, for example, β-galactosidase (encoded by lacZ gene), green fluorescent protein (GFP), enhanced green fluorescent protein (eGFP), mPlum, mCherry, tdTomato, mStrawberry, J-Red, DsRed, mOrange, mKO, mCitrine, Venus, YPet, enhanced yellow fluorescent protein (EYFP), Emerald, CyPet, cyan fluorescent protein (CFP), Cerulean, T-Sapphire, luciferase, alkaline phosphatase, or combinations thereof.
[0101] The following description is a non-limiting example that utilizes the lacZ reporter gene encoding β-galactosidase. The methods and compositions described herein can be practiced with any reporter gene.
[0102] To investigate the expression patterns of the 20 target lincRNA genes, X-gal staining for β-galactosidase activity was applied to whole embryos or whole mount tissues and organs of adult mice. The target lincRNA genes showed a variety of unique reporter gene expression patterns (Table 2 in Figure 11) and represented most of the major organ systems and tissue types. The reporter expression patterns indicate that most of the lincRNA genes are transcribed in multiple adult tissues, with one gene, Pint, ubiquitously expressed in all tissues examined. For approximately one-third of the lincRNA genes, expression was restricted to a single organ, e.g., Pantr2, Kantr, and Haglr in the brain, Mannr and Fendrr in the lung, Eldr in the urogenital system, and Halr1 in the thorax. Three of the lincRNA genes, including HOTAIR, Ptgs2os2, and Haglr, did not show expression in any adult tissues.
[0103] Embryonic expression appears to be a common feature among lincRNAs. Examination of β-galactosidase reporter expression in heterozygous embryos at or around embryonic day 12.5 (E12.5) revealed various specific patterns of 20 target lincRNA genes (Table 2 in Figure 11, Figure 2A). Expression profiles ranged from ubiquitous (Tug1) to highly restricted (e.g., epidermis for Elder, whisker placode for Trp53cor1 (Figure 9), or mammary bud for Lincenc1 (Figure 9)). The spatiotemporal patterns of differential spread of limb bud and tail expression of HOTTIP and Hoxa11os are quite similar to those reported for adjacent protein-coding genes in the HoxA cluster (Hostikka, SL, and Capecchi, MR (1998) Mech Dev 70:133-145; Lu, P. et al. (2008), Development 135:1395-14 05). The expression of HOTAIR in the posterior tail bud and genital tubercle observed for the β-galactosidase reporter was identical to that determined by in situ hybridization (Schorderet, P. and Duboule, D. (2011), PLos Genet 7:e1002071). Analysis by β-galactosidase staining at different times of embryonic development showed that some of the lincRNA genes started expressing early in a restricted area and later spread beyond this early locus (Figure 2B), again reminiscent of Hox protein expression (Nagy, A. (2003) Manipulating the mouse embryo: a laboratory manual, Cold Spring Harbor, NY, Cold Spring Hobor Laboratory Press). For example, expression of HOTTIP and Hoxa11os genes started very posteriorly in the E9.5 embryo and subsequently extended into the limb buds at later times. Similarly, initial expression of Celrr at E9.5 near the anterior end of the embryo was maintained over the next 2 days and extended along the full length of the spinal cord.
[0104] Consistent with the frequent brain expression seen among human tissue-specific lncRNAs (Derrien et al., (2012)), half of the 20 targeted mouse lincRNA genes are transcriptionally active in the brain. Similar to embryonic lincRNA expression, the brain patterns (Figure 3) varied from unique and ubiquitous (lincppara and Pint) to highly restricted (Peril, Crnde, and Kantr). Among the 20 targeted lincRNA genes, only Pint showed a global systemic expression pattern, which was mainly restricted after birth. Unique to Pint was the observed age-related increase in expression (Figure 4). In day 3 neonates, Pint transcriptional activity is low (brain) or undetectable (thoracic muscle), but gradually becomes evident in 3-week-old mice, becoming strong and ubiquitous by day 8. The intensity and timing of Pint expression varies in different organs and tissues, but the general trend is a steady increase in expression after birth, reaching a plateau in adulthood. This dynamic expression pattern with age is novel: we have not observed a similar profile in lacZ profiling experiments of hundreds of protein-coding gene knockouts.
[0105] iii. Phenotype Genetic modification of lncRNA genes can result in various phenotypes in non-human animals provided herein.Such phenotypes can include, for example, premature aging-related phenotypes, defects in various organs including brain, skeleton, muscle or lung, defects in embryonic development, perinatal or embryonic mortality, hair loss, early growth arrest, spinal curvature, or abnormal posture.
[0106] In one embodiment, a non-human animal comprising at least one modified long non-coding RNA (lncRNA) described herein is characterized by having one or more phenotypes, namely: (a) a premature aging-associated phenotype; (b) perinatal lethality; (c) defects in lung development; (d) morphological malformations of the tail and hind limbs; (e) loss of muscle mass in one or more tissues; (f) defects in brain development; or (g) any combination thereof.
[0107] In one embodiment, genetic modification of lncRNA locus causes lethality. In some cases, modification of lncRNA locus causes embryonic lethality. In one embodiment, modification of lncRNA locus causes perinatal lethality. In one embodiment, disruption or knockout of Fendrr lncRNA or Peril lncRNA causes perinatal lethality. In another embodiment, disruption or knockout of Haglr causes lethality.
[0108] In one embodiment, the genetic modification of lncRNA locus leads to premature aging-related phenotype.In such animals, the signs of premature aging can include, for example, slow weight gain, weight plateau earlier, early growth arrest, spinal curvature by 12 weeks of age, severe spinal curvature by 26 weeks of age, loss of fur at about 6 months of age, loss of hind limb strength at about 6 months of age, or combinations thereof.In one embodiment, the genetic modification that leads to premature aging-related phenotype is the disruption or knockout of Pint. In one embodiment, the lncRNA is Pint, and the human animal is characterized by premature aging-associated phenotypes including: (a) slower growth rate than wild-type controls, (b) reduced muscle strength, (c) fibrosis, (d) lower body fat content than wild-type controls, (e) lower femoral bone mineral density and bone mass than wild-type controls, (f) reduced muscle mass compared to wild-type controls, (g) reduced median life span, (h) spinal curvature, (i) organ atrophy, or (j) any combination thereof (a)-(i).
[0109] Loss-of-function genetic modification of lncRNA locus may also cause brain development defects.In one embodiment, the genetic modification that causes premature aging-related phenotype is the disruption or knockout of Pantr2, Kantr, Peril, Celrr, Pantr1, Crnde, lincenc1, Pint, lincppara or Tug1.In one specific embodiment, the lncRNA is Pantr2.In another specific embodiment, the lncRNA is Pint.
[0110] Phenotypic analysis of various examples of lincRNA knockout mice provided herein was performed and is described later in the specification.
[0111] The marked increase in whole-body Pint expression with age revealed by lacZ profiling (Fig. 4) suggests a global homeostatic role for Pint in maintaining normal health as mice age. To test this hypothesis, we bred the knockout allele homozygous and followed wild-type (WT), heterozygous (Het), and homozygous knockout (KO) mice from birth to 26 weeks of age for any obvious signs of growth rate and impaired health. Pint KO mice gained weight at a slower rate over time and reached a weight plateau earlier and at a significantly lower weight than WT mice (Fig. 5A and B), signifying a premature growth arrest. Both male and female KO and Het mice showed a slow growth phenotype, but it was more pronounced in males. Skeletal imaging by microCT analysis of individual mice with aging revealed the appearance of spinal curvature in approximately 70% of male and female Pint KO mice by 12 weeks of age, and severe spinal curvature in approximately 90% of 28-week-old KO mice (Figure 5C and D). In contrast, only 10–20% of 26-week-old WT mice showed mild age-related spinal curvature. Prominent spinal curvature did not appear in Pint Het mice until 26 weeks of age, indicating abnormal age-dependent Pint haploinsufficiency. Age-related fur loss in 6-month-old KO mice was also observed to be more severe in females (5 of 10 KOs) than in males (2 of 9), and furthermore was seen in only one Het and not WT mouse of the same age. A less severe phenotype, hindlimb grasping behavior during tail suspension, was observed in 6-month-old Pint mice compared with approximately 20% WT mice of the same age. This was seen in approximately two-thirds of the KO mice (60% of females and 67% of males). This phenotype demonstrated an age-related loss of hindlimb strength (see Figure 8 for another example of this phenotype in a HOTTIP knockout line). The breadth of mutation-associated defects in Pint knockout mice suggests a premature aging-associated phenotype.
[0112] Of 19 lincRNA knockout mouse lines bred homozygously, two (11%) (Peril and Fendrr) showed perinatal lethality (LA Goff et al., unpublished). A knockout of the Fendrr gene was recently reported (Grote et al., (2013)). The allele consisted of an insertion of a transcription stop element in the first exon. In embryos with homozygous mutations in Fendrr, Grote et al. (2013) observed lethality around E13.75, accompanied by prominent umbilical hernia, reduced ventral body wall thickness, and cardiac defects that caused blood pooling. None of these phenotypes were observed in the Fendrr knockout line described here, which has a 26 kb deletion from exon 2 to the last annotated exon (Figure 1). X-gel staining of E12.5 embryos showed lacZ expression in the frontonasal process, upper airway, lungs, and in the posterior AGM (aorta-gonad-mesonephros) region (Figure 6A), which was the same in both heterozygous (not shown) and homozygous embryos (Figure 6A). Observation of only the developing lungs at E13.5 revealed defects in the knockout embryos. The lung lobes appeared collapsed and globular and disorganized (Figure 6B). Mice homozygous for the deletion allele knockout of the Fendrr gene described herein survived to birth but died shortly after with obvious respiratory problems. The Fendrr mutant perinatal lethal phenotype was the same in mice of two different genetic backgrounds, namely the C57Bl6NTac / 129S6SvEvTac hybrid background reported here and in mice further backcrossed to the C57BL / 6 background, which presents additional husbandry problems.
[0113] Some milder phenotypes were also observed among lincRNA knockout mice that survived to maturity and showed normal Mendelian segregation of mutant alleles (LA Goff et al., unpublished). Among these, there is a strong correlation between detectable phenotype and lacZ expression in some of the lincRNA gene knockouts (e.g., Pantr2, HOTAIR, and HOTTIP). Mice homozygous for Pantr2 gene ablation (complete deletion of 6.5 kb coding sequence, Table 1) show improper development of the cerebral cortex (heavy staining in the CNS) with reduced numbers of intermediate progenitors and defects in neuronal migration affecting the development of upper layer projection neurons (LA Goff et al., unpublished). Deletion of HOTAIR and HOTTIP genes (both complete or partial gene ablations, Table 1) resulted in completely penetrant morphological malformations. In HOTAIR KO mice, we observed a clear homeotic transfection of the fourth caudal vertebra, which appears anatomically similar to the third caudal vertebra (Figure 7) (specific transient lacZ staining in the tail bud). HOTTIP KO mice (with positive staining in the embryonic limb buds) showed abnormal posture when suspended by the tail compared to wild-type littermates (Figure 8A). This behavioral abnormality was accompanied by a loss of grip endurance, measured by a test in which mice remained suspended in an inverted wire cage. Wild-type and HOTTIP Het mutants maintained a grip for approximately 1 min, whereas KO littermates ceased gripping within 10–20 s (Figure 8B). This apparent reduction in grip strength was associated with a loss of muscle mass in the gastrocnemius, but not in the tibialis anterior or quadriceps (Figure 8C). A reduction in the number of fibers in the gastrocnemius muscle by approximately 40% was observed, but no reduction in their average size was observed (Fig. 8D and E). In addition to the muscle defects in HOTTIP knockout mice, skeletal malformations were also observed, namely a reduction in the length of the hindlimb calcaneus (Fig. 10).
[0114] The last few years have seen an explosion in understanding the non-protein coding components of the genome, especially in mammals. In addition to the non-coding functional RNAs, ribosomal RNAs, transfer RNAs, small nuclear RNAs, small nucleolar RNAs, small cytoplasmic RNAs, and the RNA components RNase P, RNAse MRP, and telomerase enzymes, known for decades, as well as the more recently discovered classes of microRNAs and PIWI-associated piRNAs, we can now include at least 10,000 members of the long non-coding RNA class (Carninci et al., 2005; Derrien et al., 2012; Djebali et al., 2012; Guttman et al., 2009; Kaproanov et al., 2007). As we come to understand the genomic presence and expression of lncRNA genes, the next goal is to discover their biological functions. As a first step to begin to address this challenge, we have applied mouse knockout technology. This technology is a powerful tool for determining mammalian gene function and for creating a resource of knockout mouse lines of 20 lincRNA genes selected for dominant neural lineage expression and expected function during development.
[0115] Because lincRNAs have unknown structure-function relationships, it was crucial to create knockout alleles with deletions that removed most, if not all, of the lincRNA coding capacity to ensure that any phenotypes observed in this initial study were the result of completely null alleles. The ambiguous and complex annotation of many of the lincRNA loci, with multiple reported transcripts likely generated by alternative splicing or transcription start sites, increases the difficulty of knockout allele design and makes it difficult to construct conditional alleles that avoid the risk of hypomorphic effects. New knowledge of molecular properties important for lincRNA function will inform the design of the next generation of lincRNA alleles with more precisely directed modifications of sequences important for function, as well as allowing for sophisticated and flexible conditional conditions.
[0116] The aim of the lincRNA knockout study described herein was to create alleles that report the spatiotemporal pattern of gene expression in addition to the abolishing function. Alleles were successfully engineered that report all gene expression of 20 target genes, despite having no protein-coding open reading frames as a guide. One of the alleles that did not result in lacZ expression at maturity was Ptgs2os2 (see Figure 2A and Figure 9 for expression in embryos). It is known to be one of the lincRNAs most strongly induced by inflammatory signals (Carpenter, S. et al., (2013), Scienceexpress 01 August 2013: Guttman et al., (2009)). No validation experiments were performed in this study. However, the Ptgs2os2 knockout line should reveal a useful resource for studies on how lincRNA expression responds to infection or other inflammatory insults and what biological role it plays in the process.
[0117] The diversity and specificity of gene expression patterns observed closely resembled those seen with reporter alleles of protein-coding genes. Embryonic expression was a feature shared by nearly all lincRNA genes tested, which may indicate a common role for lincRNAs in regulating key events in development. We observed changing spatiotemporal patterns during embryogenesis that are similar to those observed for HOX proteins (Figure 2B), highly specific expression, e.g., whisker placode staining of Trp53cor1, mammary bud expression of Lincenc1 (Figures 2A and 9), ubiquitous expression in adult tissues, e.g., Pint (Figure 4), and temporal changes in expression patterns, e.g., qualitative changes seen in Celrr during embryogenesis (Figure 2B), as well as a novel quantitative increase in overall expression with age for Pint (Figure 4). As many of the lincRNA genes selected for this study were known to be expressed in natural cell lineages, brain-specific reporter expression was observed (Figure 3). However, lacZ profiling added higher resolution and richer biological information than cell or dissected tissue-based assays.
[0118] Among the phenotypes observed in 19 lincRNA knockout lines bred to homozygosity, lethality was observed twice (11%), a frequency likely lower than would be expected for the knockout of randomly selected protein-coding genes. The somewhat lower lethality and frequent embryonic expression coupled with the subtlety of nonlethal phenotypes seen in HOTAIR (Fig. 6), HOTTIP (Figs. 7 and 8), Pantr2 (LA Goff et al., unpublished), and others (M. Sauvageau et al., unpublished) suggest that lincRNAs may buffer or regulate gene expression or other processes rather than serving a single critical function. In this way, lincRNAs may resemble their smaller noncoding analogues, miRNAs, in that they may share redundant and overlapping targets and functions with other functional lncRNAs.
[0119] One goal of this study was to generate a resource of lincRNA knockout mouse lines with common allele strategy and functional reporter capacity that could serve as targets for more in-depth expression and phenotypic studies. The addition of a LacZ cassette in each case allowed for simultaneous disruption of gene function and study of the regulation of lincRNA expression patterns by X-Gal staining. These studies reveal dynamic spatial and temporal patterns of lincRNA expression during mouse embryogenesis and provide insight into the in vivo regulatory / functional properties of this new class of molecules and the precise regions where these genes may be sought throughout maturation. This study served as a model for a larger project, similar to that accomplished by the International Knockout Mouse Consortium for protein-coding genes, where all members of the lincRNA class could be mutated (Bradley et al., 2012).
[0120] II. Methods for modifying lncRNA genes in non-human animals Methods for genetically modifying lncRNA loci in non-human animals, cells, tissues, or embryos are provided herein.
[0121] Any lncRNA locus can be modified by the methods provided herein. Non-limiting examples of lncRNA genes include HOTAIR, HOTTIP, Hoxa11os (formerly known as HoxA11as), Pantr1 (formerly known as lincRNA-Brn1-a), Pantr2 (formerly known as lincRNA-Brn1-b), Ptgs2os2 (formerly known as lincRNA-COx2), Eldr (formerly known as Fabl and lincRNA-Egfr), Lincenc1 (formerly known as lincRNA-Enc1), Mannr (formerly known as lincRNA-Evi1), Fendrr (formerly known as lincRNA-FOxf1), Halr1 (formerly known as Haunt and lincRNA-HoxA1), H aglr (formerly known as Mdgt and lincRNA-HoxD3), Celrr (formerly known as Celr and lincRNA-Insig2), Crnde (formerly known as lincRNA-Irx5), Kantr (formerly known as Spasm and lincRNA-Jarid1c), Pint (formerly known as linc-Pint and lincRNA-Mkln1), Trp53cor1 (formerly known as lincRNA-p21), lincppara (formerly known as lincRNA-Ppara), Peril (formerly known as lincRNA-Sox2), Tug1 (formerly known as lincRNA-Tug1), or any combination thereof.
[0122] In one embodiment, a method for modifying a lncRNA locus of interest in a pluripotent cell is provided. Such a method includes (a) introducing into the pluripotent cell a targeting construct comprising an insert nucleic acid flanked by 5' and 3' homology arms capable of undergoing homologous recombination with the lncRNA locus in the genome of the cell, and (b) identifying a modified pluripotent cell comprising a targeted genetic modification at the lncRNA locus. In such a method, the genetic modification results in a loss of function of the lncRNA. In one embodiment, the pluripotent cell is a mouse or rat embryonic stem cell. In another embodiment, the pluripotent cell is a human iPS cell.
[0123] A. Targeting Vectors and Insert Nucleic Acids Further provided are targeting vectors or targeting constructs for use in the methods of making genetically modified non-human animals, cells, tissues, or embryos provided herein.
[0124] In one embodiment, a targeting vector includes an insert nucleic acid flanked by 5' and 3' homology arms capable of homologous recombination with a lncRNA locus of interest. is provided.
[0125] Examples of targeting vectors and components of the targeting vectors (ie, insert nucleic acid, polynucleotide of interest, expression cassette, etc.) are described in detail herein below.
[0126] i. Insert Nucleic Acid An "insertion nucleic acid" or "insertion polynucleotide" comprises a segment of DNA that is desired to be integrated at a target locus. In one embodiment, the insert nucleic acid comprises one or more polynucleotides of interest. In other embodiments, the insert nucleic acid comprises one or more expression cassettes. A given expression cassette comprises a polynucleotide of interest, a polynucleotide encoding a selectable marker, and / or a reporter gene, along with various regulatory components that affect expression.
[0127] Any of the polynucleotides of interest may be included in various insert polynucleotides and thereby integrated at the target genomic locus. The methods disclosed herein provide for at least one, two, three, four, five, six, or more polynucleotides of interest to be integrated into the target lncRNA genomic locus of interest.
[0128] In one embodiment, the polynucleotide of interest contained in the insert nucleic acid encodes a reporter, hi another embodiment, the polynucleotide of interest encodes a selectable marker.
[0129] In one embodiment, the polynucleotide of interest is flanked by site-specific recombination sites. In a specific embodiment, the site-specific recombination sites flank the segment encoding the reporter and / or the segment encoding the selectable marker.
[0130] Non-limiting examples of polynucleotides of interest, including selectable markers and reporter genes that can be included in the insert nucleic acid, are described in detail elsewhere herein.
[0131] A polynucleotide of interest within the inserted polynucleotide upon integration at the target lncRNA locus may introduce one or more genetic modifications into the cell. The genetic modification may include a deletion of an endogenous nucleic acid sequence and / or the addition of an exogenous or non-homologous or orthologous polynucleotide into the target genomic locus. In one embodiment, the genetic modification includes replacing an endogenous nucleic acid sequence with an exogenous polynucleotide of interest at the genomic locus. Thus, the methods provided herein allow for the generation of genetic modifications including knockouts, deletions, insertions, substitutions ("knock-ins", point mutations, domain swaps, exon swaps, intron swaps, regulatory sequence swaps, gene swaps, or combinations thereof at the target lncRNA locus. Such modifications may occur by integration of the first, second, third, fourth, fifth, sixth, seventh, or any subsequent inserted polynucleotide into the target genomic locus.
[0132] The polynucleotide of interest within the insert polynucleotide or / and integrated at the target genomic locus may be composed of sequences that are native or homologous to the cell into which it is introduced. The polynucleotide of interest may be heterologous to the cell into which it is introduced. The polynucleotide of interest may be exogenous to the cell into which it is introduced. The polynucleotide of interest may be orthologous to the cell into which it is introduced. Or, the polynucleotide of interest may originate from a different species than the cell into which it is introduced. The term "homologous" in relation to a sequence is a sequence that is native to the cell. The term "heterologous" in relation to a sequence is a sequence that is derived from a foreign species or, if from the same species, that is substantially modified by deliberate human intervention in the native composition and / or genomic locus. The term "exogenous" in relation to a sequence is a sequence that is derived from a foreign species. The term "orthologous" is a polynucleotide from one species that is functionally equivalent to a known reference sequence of another species (i.e., a variant). The polynucleotide of interest may be derived from any organism of interest, including, but not limited to, prokaryote, eukaryote, non-human, rodent, hamster, mouse, rat, human, monkey, bird, agricultural mammal, or non-agricultural mammal. The polynucleotide of interest may further comprise coding regions, non-coding regions, regulatory regions, or genomic DNA. Thus, the first, second, third, fourth, fifth, sixth, seventh, and / or any subsequent inserted polynucleotides may comprise such sequences.
[0133] In one embodiment, the polynucleotide of interest can range from about 500 nucleotides to about 200 kb, as described above. The polynucleotide of interest can range from about 500 nucleotides to about 5 kb, about 5 kb to about 200 kb, about 5 kb to about 10 kb, about 10 kb to about 20 kb, about 20 kb to about 30 kb, about 30 kb to about 40 kb, about 40 kb to about 50 kb, about 60 kb to about 70 kb, about 80 kb to about 90 kb, about 90 kb to about 100 kb, The length of the nucleic acid sequence may be up to about 100 kb, about 100 kb to about 110 kb, about 120 kb to about 130 kb, about 130 kb to about 140 kb, about 140 kb to about 150 kb, about 150 kb to about 160 kb, about 160 kb to about 170 kb, about 170 kb to about 180 kb, about 180 kb to about 190 kb, or about 190 kb to about 200 kb.
[0134] The polynucleotide of interest within the insert polynucleotide and / or inserted at the target genomic locus can encode a polypeptide, can encode an RNA, can encode an miRNA, or can include any regulatory or non-coding region of interest, including, but not limited to, a regulatory sequence, a promoter sequence, an enhancer region, a transcriptional repressor binding break, a Kozak consensus segment, a start codon, or a deletion of a non-protein coding sequence, but not including a deletion of a protein coding sequence. Additionally, the polynucleotide of interest within the insert polynucleotide and / or inserted at the target genomic locus can encode a protein expressed in the nervous system, skeletal system, digestive system, circulatory system, muscular system, respiratory system, cardiovascular system, lymphatic system, endocrine system, urinary system, reproductive system, or a combination thereof.
[0135] In one embodiment, the insert nucleic acid comprises a knock-in allele of at least one exon of the endogenous gene. In one embodiment, the insert nucleic acid comprises a knock-in allele of the entire endogenous gene (i.e., a "gene swap knock-in").
[0136] In one embodiment, the insert nucleic acid comprises a regulatory element, such as, for example, a promoter, enhancer, or a transcriptional repression binding element.
[0137] In a further embodiment, the insert nucleic acid comprises a conditional allele. In one embodiment, the conditional allele is a multifunctional allele as described in US2011 / 0104799 (incorporated by reference in its entirety). In a specific embodiment, the conditional allele comprises: (a) an operating sequence in sense orientation relative to the transcription of a target gene, and a drug selection cassette in sense or antisense orientation; (b) a nucleotide sequence of interest (NSI) in antisense orientation, and a conditional inversion module (COIN utilizing exon split intron and invertible gene trap-like module, see, for example, US2011 / 0104799, which is incorporated by reference in its entirety); and (c) a recombinable unit that recombines upon exposure to a first recombinase to form a conditional allele that (i) lacks the initiation sequence and DSC, and (ii) contains the NSI in sense orientation and the COIN in antisense orientation.
[0138] In one embodiment, the inserted nucleic acid comprises a genetic modification in a coding sequence. In one embodiment, the genetic modification comprises a deletion mutation in the coding sequence. In one embodiment, the genetic modification comprises a fusion of two endogenous coding sequences.
[0139] In one embodiment, the genetic modification comprises the deletion of a non-protein coding sequence, but not the deletion of a protein coding sequence. In one embodiment, the deletion of a non-protein coding sequence comprises the deletion of a lncRNA locus or a portion thereof. In one embodiment, the deletion of a non-protein coding sequence comprises the deletion of a regulatory element. In one embodiment, the genetic modification comprises the deletion of a promoter. In one embodiment, the genetic modification comprises the addition of a promoter or a regulatory element. In one embodiment, the genetic modification comprises the replacement of a promoter or a regulatory element.
[0140] In one embodiment, the nucleic acid sequence of the targeting vector comprises a polynucleotide that, when integrated into the genome, results in a genetic modification of a region of a lncRNA locus of a mammal, non-human animal, or non-human mammal. Here, the genetic modification in the lncRNA results in a loss of function of the lncRNA. In one embodiment, a lncRNA knockout ("null allele") is generated. In another embodiment, a disruption of the lncRNA locus is generated.
[0141] In a further embodiment, the insert nucleic acid results in the replacement of a portion of the mammal, non-human animal, or non-human mammal lncRNA locus with the insert nucleic acid sequence. In one embodiment, the insert nucleic acid sequence is a reporter nucleic acid sequence.
[0142] A given insertion polynucleotide and the corresponding region of the mammalian, non-human animal, or non-human mammalian locus that is being replaced can be a non-coding region, a coding region, an intron, an exon, an untranslated region, a regulatory region, a promoter, or an enhancer, or any combination thereof. Furthermore, a given insertion polynucleotide and / or region of the mammalian, non-human animal, or non-human mammalian locus that is being deleted can be of any desired length, including, for example, between 10 and 100 nucleotides in length, between 100 and 500 nucleotides in length, between 500 and 1 kb nucleotides in length, between 1 kb and 1.5 kb nucleotides in length, between 1.5 kb and 2 kb nucleotides in length, between 2 kb and 2.5 kb nucleotides in length, between 2.5 kb and 3 kb nucleotides in length, between 3 kb and 5 kb nucleotides in length, between 5 kb and 8 kb nucleotides in length, and between 8 kb and 10 kb nucleotides in length. In other examples, the size of the insertion or substitution is from about 5k to about 10kb, from about 10kb to about 20kb, from about 20kb to about 40kb, from about 40kb to about 60kb. In other embodiments, a given insertion polynucleotide and / or a genetic locus in a mammal, human cell, or non-human mammal that is deleted is at least 100, 200, 300, 400, 500, 600, 700, 800, or 900 nucleotides, or at least 1 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 7 kb, 8 kb, 9 kb, 10 kb, 11 kb, 12 kb, 13 kb, 14 kb, 15 kb, 16 kb, 17 kb, 18 kb, 19 kb, 20 kb, 25 kb, 30 kb, 35 kb, 40 kb, 45 kb, 50 kb, or more.
[0143] In one embodiment, the insert nucleic acid is inserted into the lncRNA locus of interest so that it is operably linked to the endogenous lncRNA promoter.In such a case, the lncRNA promoter drives the expression of the insert nucleic acid sequence.In one embodiment, the insert nucleic acid sequence is a reporter nucleic acid sequence.
[0144] In some cases, the insert nucleic acid comprises a promoter. In one embodiment, the insert nucleic acid comprises a polynucleotide of interest operably linked to a promoter that drives expression of the polynucleotide of interest. In one embodiment, the polynucleotide of interest comprises a reporter nucleic acid sequence. In another embodiment, the polynucleotide of interest comprises a selectable marker nucleic acid sequence.
[0145] In one embodiment, the promoter is a constitutively active promoter.
[0146] In one embodiment, the promoter is an inducible promoter. In one embodiment, the inducible promoter is a chemically regulated promoter. In one embodiment, the chemically regulated promoter is an alcohol regulated promoter. In one embodiment, the alcohol regulated promoter is an alcohol dehydrogenase (alcA) gene promoter. In one embodiment, the chemically regulated promoter is a tetracycline regulated promoter. In one embodiment, the tetracycline regulated promoter is a tetracycline responsive promoter. In one embodiment, the tetracycline regulated promoter is a tetracycline operator sequence (tetO). In one embodiment, the tetracycline regulated promoter is a tet-On promoter. In one embodiment, the tetracycline regulated promoter is a tet-Off promoter. In one embodiment, the chemically regulated promoter is a steroid regulated promoter. In one embodiment, the steroid regulated promoter is a rat glucocorticoid receptor promoter. In one embodiment, the steroid regulated promoter is an estrogen receptor promoter. In one embodiment, the steroid regulated promoter is an ecdysone receptor promoter. In one embodiment, the chemically regulated promoter is a metal regulated promoter. In one embodiment, the metal regulated promoter is a metalloprotein promoter. In one embodiment, the inducible promoter is a physically regulated promoter. In one embodiment, the physically regulated promoter is a temperature regulated promoter. In one embodiment, the temperature regulated promoter is a heat shock promoter. In one embodiment, the physically regulated promoter is a light regulated promoter. In one embodiment, the light regulated promoter is a light inducible promoter. In one embodiment, the light regulated promoter is a light repressible promoter.
[0147] In one embodiment, the promoter is a tissue specific promoter. In one embodiment, the promoter is a neural specific promoter. In one embodiment, the promoter is a glial specific promoter. In one embodiment, the promoter is a muscle cell specific promoter. In one embodiment, the promoter is a cardiac cell specific promoter. In one embodiment, the promoter is a kidney cell specific promoter. In one embodiment, the promoter is a bone cell specific promoter. In one embodiment, the promoter is an endothelial cell specific promoter. In one embodiment, the promoter is an immune cell specific promoter. In one embodiment, the immune cell promoter is a B cell promoter. In one embodiment, the immune cell promoter is a T cell promoter.
[0148] In one embodiment, the promoter is a developmentally-regulated promoter. In one embodiment, the developmentally-regulated promoter is active only during the embryonic stage of development. In one embodiment, the developmentally-regulated promoter is active only in mature cells.
[0149] In specific embodiments, promoters can be selected according to cell type.Therefore, various promoters find use in eukaryotic cells, mammalian cells, non-human mammals, pluripotent cells, human pluripotent cells, human ES cells, human adult stem cells, developmentally restricted human progenitor cells, human iPS cells, human cells, rodent cells, rat cells, mouse cells, hamster cells, fibroblasts, or CHO cells.
[0150] In some embodiments, the insert nucleic acid comprises a nucleic acid flanked by site-specific recombination target sequences. While the entire insert nucleic acid may be flanked by such site-specific recombination target sequences, any region or individual polynucleotide of interest within the insert nucleic acid may also be flanked by such sites. The site-specific recombinase may be introduced into the cell by any means. Such means include introducing a recombinase polypeptide into the cell or introducing a polynucleotide encoding the site-specific recombinase into the host cell. The polynucleotide encoding the site-specific recombinase may be located within the insert nucleic acid or within another polynucleotide. The site-specific recombinase may be operably linked to a promoter active within the cell. Such promoters include, for example, an inducible promoter, a promoter endogenous to the cell, a promoter heterologous to the cell, a cell-specific promoter, a tissue-specific promoter, or a developmental stage-specific promoter. Site-specific recombination target sequences that can flank the insert nucleic acid or any polynucleotide of interest within the insert nucleic acid can include, but are not limited to, loxP, lox511, lox2272, lox66, lox71, loxM2, lox5171, FRT, FRT11, FRT71, attp, att, FRT, rox, or combinations thereof.
[0151] In some embodiments, the site-specific recombination sites flank a polynucleotide encoding a selectable marker and / or a reporter gene contained within the insert nucleic acid sequence. In such cases, following integration of the insert nucleic acid at the target locus, the sequence between the site-specific recombination sites can be removed.
[0152] In one embodiment, the insert nucleic acid comprises a polynucleotide encoding a selection marker. The selection marker may be included in a selection cassette. Such selection markers include, but are not limited to, neomycin phosphotransferase (neomycin phosphotransferase). r), hygromycin B phosphotransferase (hyg r ), puromycin N-acetyltransferase (puro r ), Blasticidin S deaminase (bsr r ), xanthine / guanine phosphoribosyl transferase (gpt) or herpes simplex virus thymidine kinase (HSV-k), or a combination thereof. In one embodiment, the polynucleotide encoding the selection marker is operably linked to a promoter active in the cell. In one embodiment, the polynucleotide encoding the selection marker is flanked by site-specific recombination target sequences.
[0153] The insert nucleic acid further comprises a reporter gene operably linked to the promoter, where the reporter gene encodes a reporter protein selected from the group consisting of β-galactosidase (encoded by the lacZ gene), GFP, mPlum, mCherry, tdTomato, mStrawberry, J-Red, DsRed, mOrange, mKO, mCitrine, Venus, YPet, enhanced yellow fluorescent protein (EYFP), Emerald, enhanced green fluorescent protein (EGFP), CyPet, cyan fluorescent protein (CFP), Cerulean, T-Sapphire, luciferase, alkaline phosphatase, and / or combinations thereof. Such reporter genes may be operably linked to a promoter that is active in the cell, which may be an inducible promoter, a promoter that is endogenous to the reporter gene or the cell, a promoter that is heterologous to the reporter gene or the cell, a cell-specific promoter, or a developmental stage-specific promoter.
[0154] In one embodiment, the genetic modification comprises a deletion of a non-protein coding sequence, but does not comprise a deletion of a protein coding sequence. In one embodiment, the deletion of a non-protein coding sequence comprises a deletion of a lncRNA locus or a portion thereof. In one embodiment, the deletion of a non-protein coding sequence comprises a deletion of a regulatory element. In one embodiment, the genetic modification comprises a deletion of a regulatory element. In one embodiment, the genetic modification comprises a replacement of a promoter or regulatory element. In one embodiment, the genetic modification comprises a replacement of a promoter or regulatory element.
[0155] ii. Expression cassette Provided herein are polynucleotides or nucleic acid molecules that include various components used in the targeted genome integration systems provided herein to target lncRNA loci (i.e., any one or any combination of nuclease agents, recognition sites, insert nucleic acids, polynucleotides of interest, reporter sequences, targeting vectors, selectable markers, and other components).
[0156] The terms "polynucleotide", "polynucleotide sequence", "nucleic acid sequence", and "nucleic acid fragment" are used interchangeably herein. These terms include nucleotide sequences and others. A polynucleotide may be a polymer of RNA or DNA that is single-stranded or double-stranded, and optionally contains synthetic, non-natural, or modified nucleotide bases. A polynucleotide in the form of a polymer of DNA may be composed of one or more segments of cDNA, genomic DNA, synthetic DNA, or mixtures thereof. A polynucleotide may include deoxyribonucleotides, including ribonucleotides, both naturally occurring molecules and synthetic analogs, and any combination thereof. A polynucleotide provided herein also includes all forms of sequences. Such sequences include, but are not limited to, single-stranded forms, double-stranded forms, hairpins, stem-and-loop structures, and others.
[0157] Further provided is a recombinant polynucleotide comprising various components of a targeted genome integration system that targets lncRNA loci. The terms "recombinant polynucleotide" and "recombinant DNA construct" are used interchangeably. A recombinant construct comprises an artificial or non-homologous combination of nucleic acid sequences (e.g., control and coding sequences that are not found together in nature). In other embodiments, a recombinant construct may comprise control and coding sequences that are derived from different sources, or control and coding sequences that are derived from the same source but arranged in a manner different from that found in nature. Such a construct may be used by itself or may be used together with a vector. When a vector is used, the choice of vector depends on the method used to transform the host, which is well known to those skilled in the art. For example, a plasmid vector may be used. Also provided are the genetic elements required to successfully transfect, select, and grow a host cell that comprises any of the isolated nucleic acid fragments provided herein. Screening may be done by Southern analysis of DNA, Northern analysis of mRNA expression, immunoblotting analysis of protein expression, or phenotypic analysis, among others.
[0158] In a specific embodiment, one or more components of the targeted genome integration system for targeting lncRNA loci described herein can be provided in an expression cassette for expression in prokaryotic, eukaryotic, bacterial, yeast, or mammalian cells, or other organisms or cell types of interest. The cassette can include 5' and 3' control sequences operably linked to the polynucleotides provided herein. "Operably linked" includes a relationship in which the operably linked components function in an intended manner. For example, an operably linked link between a polynucleotide of interest and a control sequence (i.e., a promoter) is a functional linkage that allows for expression of the polynucleotide of interest. The operably linked elements can be contiguous or discontinuous. When used in reference to the connection of two protein coding regions, operably linked means that these coding regions are in the same reading frame. In another example, a nucleic acid sequence encoding a protein can be operably linked to linked control sequences (e.g., promoters, enhancers, silencer sequences, etc.) to maintain proper transcriptional regulation. The cassette may contain at least one additional polynucleotide of interest that is introduced into the organism together. Alternatively, the additional polynucleotides of interest can be provided in multiple expression cassettes. Such expression cassettes are provided with multiple restriction and / or recombination sites for the insertion of recombinant polynucleotides that are under the transcriptional control of the regulatory regions. The expression cassette may further contain a selectable marker gene.
[0159] An expression cassette can include, in the 5'-3' direction of transcription, a transcriptional and translational initiation region (i.e., a promoter), a recombinant polynucleotide provided herein, and a transcriptional and translational termination region (i.e., a termination region) functional in a mammalian cell or host cell of interest. The regulatory regions (i.e., the transcriptional regulatory region of the promoter, the Kozak sequence, and the translational termination region) and / or polynucleotides provided herein can be native / analogous to the host cell or to each other. Alternatively, the regulatory regions and / or polynucleotides provided herein can be heterologous to the host cell or to each other. For example, a promoter operably linked to a heterologous polynucleotide can be from a species different from the species from which the polynucleotide was derived, or, if from the same / analogous species, one or both can be substantially modified from their original form and / or genomic locus, or the promoter is not the native promoter of the operably linked polynucleotide. Alternatively, the regulatory regions and / or recombinant polynucleotides provided herein can be entirely synthetic.
[0160] The termination region may be native to the transcription initiation region, may be native to a recombinant polynucleotide to which it is operably linked, may be native to the host cell, or may be derived from another source (i.e., foreign or heterologous) to the promoter, recombinant polynucleotide, host cell, or any combination thereof.
[0161] In preparing the expression cassettes, the various DNA fragments may be manipulated to provide the DNA sequences in the proper orientation. For this purpose, adapters or linkers may be used to join the DNA fragments together, or other manipulations may be involved, such as providing convenient restriction sites, removing excess DNA, removing restriction sites, or the like. This focus may involve in vitro mutagenesis, primer modification, restriction, annealing, and resubstitutions (e.g., transitions and transversions).
[0162] Several promoters can be used in the expression cassettes provided herein. The promoters can be selected based on the desired outcome. It is recognized that different applications can be enhanced by using different promoters in the expression cassette to adjust the timing, location, and / or level of expression of the polynucleotide of interest. Such expression constructs can also include promoter regulatory regions (e.g., inducible, constitutive, environmentally, or developmentally regulated, or cell or tissue specific / selective expression), transcription initiation start sites, Kozak consensus sequences, ribosome binding sites, RNA processing signals, transcription termination sites, and / or polyadenylation signals, as needed.
[0163] An expression cassette comprising a polynucleotide provided herein may also contain a selectable marker for selecting transfected cells. The selectable marker gene is utilized for the selection of transfected cells or tissues.
[0164] If desired, sequences used in the methods and compositions (i.e., polynucleotides of interest, nuclease factors, etc.) can be optimized for increased expression in cells. That is, genes can be synthesized using codons that are preferred in a given cell of interest. Such codons include, for example, mammalian-preferred codons, human-preferred codons, rodent-preferred codons, mouse-preferred codons, rat-preferred codons, hamster-preferred codons, etc., for improved expression.
[0165] Various methods and compositions provided herein may employ a selection marker. A variety of selection markers may be used in the methods and compositions disclosed herein. Such selection markers may confer resistance to antibiotics, such as, for example, G418, hygromycin, blasticidin, neomycin, or puromycin. Such selection markers include neomycin phosphotransferase (neomycin phosphotransferase), and the like. r ), hygromycin B phosphotransferase (hygr ), puromycin N-acetyltransferase (puro r ), and blasticidin S deaminase (bsr r In yet other embodiments, the selection marker is operably linked to an inducible promoter, and expression of the selection marker is toxic to the cell. Non-limiting examples of such selection markers include xanthine / guanine phosphoribosyltransferase (gpt), hypoxanthine-guanine phosphoribosyltransferase (HGPRT), or herpes simplex virus thymidine kinase (HSV-TK). The polynucleotide encoding the selection marker is operably linked to a promoter active in the cell.
[0166] iii. Targeting Vector The targeting vector is used to introduce an insert nucleic acid into a lncRNA locus of interest of a eukaryotic, non-human, mammalian, non-human mammalian, human, rodent, mouse, rat, or hamster nucleic acid. The targeting vector comprises an insert nucleic acid and further comprises 5' and 3' homology arms flanking the insert nucleic acid. These homology arms flanking the insert nucleic acid correspond to regions within the targeted lncRNA locus of the eukaryotic, non-human, mammalian, non-human mammalian, human, rodent, mouse, rat, or hamster nucleic acid. For ease of reference, the corresponding cognate genomic region within the targeted genomic locus is referred to as a "target site." For example, the targeting vector may comprise a first insert nucleic acid flanked by first and second homology arms that are complementary to the first and second target sites. In this manner, the targeting vector aids in the integration of the insert nucleic acid into the target locus nucleic acid via homologous recombination that occurs between the homology arms and a complementary target site within the genome of the cell.
[0167] In one embodiment, the eukaryotic, mammalian, non-human mammalian, human, rodent, mouse, or hamster nucleic acid comprises a first nucleic acid sequence complementary to the 5' homology arm and a second nucleic acid sequence complementary to the 3' homology arm. In one embodiment, the first and second nucleic acid sequences are separated by at least 5 kb. In another embodiment, the first and second nucleic acid sequences are separated by at least 1 kb, but less than 50 kb. In one embodiment, the first and second nucleic acid sequences are separated by at least 3 kb, at least 4 kb, at least 5 kb, at least 6 kb, at least 7 b, at least 8 kb, at least 9 kb, at least 10 kb, at least 15 kb, at least 20 kb, at least 30 kb, at least 40 kb, or at least 50 kb. In further embodiments, the first and second nucleic acid sequences are separated by at least 1 kb but less than 2 kb, at least 2 kb but less than 3 kb, at least 4 kb but less than 5 kb, at least 5 kb but less than 6 kb, at least 6 kb but less than 7 kb, at least 7 kb but less than 8 kb, at least about 8 kb but less than 9 kb, at least 9 kb but less than 10 kb, or at least 10 kb but less than 15 kb, at least about 15 kb but less than about 20 kb, at least about 20 kb but less than about 30 kb, or 40 kb but less than about 50 kb.
[0168] The homology arms of the targeting vector can be of any length sufficient to promote homologous recombination with the corresponding target site, such as 5-10 kb, 5-15 kb, 10-20 kb, 20-30 kb, 30-40 kb, 40-50 kb, 50-60 kb, 60-70 kb, 70-80 kb, 80-90 kb, 90-100 kb, 100-110 kb, 110-120 kb, 120-130 kb, 130-140 kb, 140-150 kb, 150-160 kb, 160-170 kb, 170-180 kb, 180-190 kb, 190-200 kb, or more. As will be outlined in more detail below, larger targeting vectors can use longer targeting arms. In a specific embodiment, the total size of the 5' homology arm and the 3' homology arm is at least 10 kb, or the total size of the 5' homology arm and the 3' homology arm is at least 16 kb to about 100 kb, or 30 kb to about 100 kb. In other embodiments, the total size of the 5' homology arm and the 3' homology arm of the LTVEC is about 10 kb to about 150 kb, about 10 kb to about 100 kb, about 10 kb to about 75 kb, about 20 kb to about 150 kb, about 20 kb to about 100 kb, about 20 kb to about 75 kb, about 30 kb to about 150 kb, about 30 kb to about 100 kb, about 30 kb to about 75 kb, about 40 kb to about 150 kb, or about 40 kb to about 150 kb. 0 kb, about 40 kb to about 100 kb, about 40 kb to about 75 kb, about 50 kb to about 150 kb, about 50 kb to about 100 kb, or about 50 kb to about 75 kb, about 10 kb to about 30 kb, about 20 kb to about 40 kb, about 40 kb to about 60 kb, about 60 kb to about 80 kb, about 80 kb to about 100 kb, about 100 kb to about 120 kb, or about 120 kb to about 150 kb. In one embodiment, the size of the deletion is the same as or similar to the total size of the 5' homology arm and the 3' homology arm of the LTVEC.
[0169] A homology arm and a target site (i.e., cognate genomic region) are "complementary" or "complementary" to one another if the two regions share a sufficient degree of sequence identity with each other to act as substrates for a homologous recombination reaction. "Homology" refers to a DNA sequence that is identical to or has sequence identity to a corresponding or "complementary" sequence. The sequence identity between a given target site and a corresponding homology arm found on a targeting vector can be any degree of sequence identity that allows homologous recombination to occur. For example, the amount of sequence identity shared by the homology arms (or fragments thereof) and the target site (or fragments thereof) of the targeting vector is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity. Furthermore, the complementary region involved in the homology between the homology arms and the complementary target site can be of any length sufficient to promote homologous recombination at the cleaved recombination site. For example, a given homology arm and / or complementary target site can include a complementary region of homology, the length of which can be at least 5-10 kb, 5-15 kb, 10-20 kb, 20-30 kb, 30-40 kb, 40-50 kb, 50-60 kb, 60-70 kb, 70-80 kb, 80-90 kb, 90-100 kb, 100-120 kb, 120-140 kb, 140-160 kb, 160-180 kb, 180-200 kb, 190-210 kb, 220-240 kb, 240-260 kb, 280-290 kb, 300-320 kb, 320-360 kb, 360-380 kb, 380-400 kb, 380-400 kb, 380-500 kb, 380-600 kb, 380-700 kb, 380-800 kb, 380-900 kb, 380-1900 kb, 380-1900 kb, 380-2100 kb, 380-2100 kb, 380-3900 kb, 380-400 kb, 380-400 kb, 380-500 kb, 380-600 kb, 380-700 kb, 380-800 kb, 380-900 kb, 380-1900 kb, 380-2100 kb, 380-2100 kb, 30 kb, 30-40 kb, 40-50 kb, 50-60 kb, 60-70 kb, 70-80 kb, 80-90 kb, 90-100 kb, 100-110 kb, 110-120 kb, 120-130 kb, 130-140 kb, 140-150 kb, 150-160 kb, 160-170 kb, 170-180 kb, 180-190 kb, 190-200 kb, 200 kb-300 kb, or more. For ease of reference, the homology arms are referred to herein as 5' homology arms and 3' homology arms. The term refers to the relative position of the homology arm to the insert nucleic acid within the targeting vector.
[0170] Thus, the homology arms of the targeting vector are designed to be complementary to the target site with the targeted locus. Thus, the homology arms can be complementary to a locus native to the cell, or the homology arms can be complementary to a region of a heterologous or foreign segment of DNA integrated into the genome of the cell, including but not limited to a transgene, an expression cassette, or a heterologous or foreign region of genomic DNA. Alternatively, the homology arms of the targeting vector can be complementary to a human artificial chromosome or any other modified genomic region contained in a suitable host cell. Furthermore, the homology arms of the targeting vector can be complementary to or derived from a region of a BAC library, a cosmid library, or a P1 phage library. Thus, in a specific embodiment, the homology arms of the targeting vector are complementary to a eukaryotic, non-human, mammalian, non-human mammalian, human, rodent, mouse, or rat genomic locus native, heterologous, or foreign to a given cell. In one embodiment, the homology arms are derived from synthetic DNA.
[0171] The targeting vector (e.g., large targeting vector) also includes a selection cassette or reporter, as discussed elsewhere herein. The selection cassette may include a nucleic acid sequence encoding a selection marker, where the nucleic acid sequence is operably linked to a promoter, as discussed elsewhere herein. The selection marker and / or reporter of the targeting vector may be flanked by 5' and 3' homology arms, or may be either 5' or 3' relative to the homology arms.
[0172] In one embodiment, the targeting vector comprises an insert nucleic acid comprising a first nucleotide sequence encoding a reporter. Optionally, following homologous recombination with the lncRNA locus of interest, the first nucleotide sequence encoding the reporter is operably linked to an endogenous promoter that drives the expression of the lncRNA at the lncRNA locus. In a further embodiment, the insert nucleic acid sequence of the targeting vector comprises a Kozak consensus sequence. In such cases where the insert nucleic acid comprises a reporter, the Kozak consensus sequence can be operably linked to the nucleic acid sequence encoding the reporter.
[0173] In another embodiment, the insert nucleic acid of the targeting vector comprises a second nucleotide sequence encoding a selectable marker. Optionally, the second nucleic acid is operably linked to a promoter.
[0174] In one embodiment, the first and / or second nucleotide sequence of the insert nucleic acid comprises a Kozak consensus sequence.
[0175] In one embodiment, the targeting vector (e.g., a large targeting vector) comprises a reporter gene and / or a selectable marker gene operably linked to a promoter, as described elsewhere herein. Such reporter gene and / or selectable marker gene may be operably linked to a promoter active in the cell.
[0176] In one embodiment, the targeting vector comprises a site-specific recombinase gene. In one embodiment, the site-specific recombinase gene encodes a Cre recombinase. In one embodiment, the Cre recombinase gene is Crei, where the two exons encoding the Cre recombinase are separated by an intron to prevent its expression in prokaryotic cells. In one embodiment, the site-specific recombinase gene encodes a Dre recombinase.
[0177] In one embodiment, the promoter suitable for expression of the Cre recombinase gene further comprises a nuclear localization signal to promote nuclear localization of Cre (or any recombinase or nuclease factor) (e.g., the gene is the NL-Cre gene). In a specific embodiment, the Cre recombinase gene further comprises a nuclear localization signal and an intron (e.g., NL-Crei).
[0178] In various embodiments, the Cre or Crei recombinase is selected from Prm1, Blimp1, Gata6, Gata4, Igf2, Lhx2, Lhx5, and / or Pax3. In a specific embodiment, the promoter is a Gata6 or Gata4 promoter. The various promoters can be derived from any organism. Such organisms include, for example, rodents, such as mice or rats, eukaryotes, non-human animals, mammals, humans, or hamsters. In another specific embodiment, the promoter is a Prml promoter. In another specific embodiment, the promoter is a mouse Prm1 promoter. In another specific embodiment, the promoter is a Blimp1 promoter or a fragment thereof, such as a 1 kb or 2 kb fragment of the Blimp1 promoter. See, for example, U.S. Pat. No. 8,697,851 and U.S. Pat. App. Pub. No. 2013-0312129, both of which are incorporated herein by reference in their entirety.
[0179] In one embodiment, the insert nucleic acid comprises a nucleotide sequence flanked by two site-specific recombination sites, including but not limited to loxP, lox511, lox2272, lox66, lox71, loxM2, lox5171, FRT, FRT11, FRT71, attp, att, FRT, rox, and combinations thereof.
[0180] iv. Large targeting vectors The term "large targeting vector" or LTVEC" includes large targeting vectors that contain homology arms that correspond to and are derived from larger nucleic acid sequences than generally used by other approaches intended to perform homologous targeting, and / or contain an insert polynucleotide that contains a larger nucleic acid sequence than generally used by other approaches intended to perform homologous recombination targeting in cells. In specific embodiments, the homology arms and / or insert polynucleotides of the LTVEC contain genomic sequences of eukaryotic cells. The size of the LTVEC is too large to allow screening when targeting by conventional assays, such as Southern blotting, long-range (e.g., 1 kb to 5 kb) PCR. Examples of LTVEC include, but are not limited to, bacterial artificial chromosome (BAC)-derived vectors, human artificial chromosomes, or yeast artificial chromosomes (YAC). Non-limiting examples of LTVECs and methods of making them are described, for example, in U.S. Patent Nos. 6,586,251, 6,596,541, 7,105,348, and WO 2002 / 036789 (PCT / US01 / 45375), each of which is incorporated herein by reference.
[0181] The LTVEC can be of any length, including, but not limited to, at least about 10 kb, about 15 kb, about 20 kb, about 30 kb, about 40 kb, about 50 kb, about 60 kb, about 70 kb, about 80 kb, about 90 kb, about 100 kb, about 150 kb, about 200 kb, about 10 kb to about 15 kb, about 15 kb to about 20 kb, about 20 kb to about 30 kb, about 30 kb to about 50 kb, about 50 kb to about 300 kb, or about 50 kb to about 300 kb. kb, about 50 kb to about 75 kb, about 75 kb to about 100 kb, about 100 kb to 125 kb, about 125 kb to about 150 kb, about 150 kb to about 175 kb, about 175 kb to about 200 kb, about 200 kb to about 225 kb, about 225 kb to about 250 kb, about 250 kb to about 275 kb, or about 275 kb to about 300 kb.
[0182] In one embodiment, the homology arms of the LTVEC are obtained from a BAC library, a cosmid library, or a PI phage library. In other embodiments, the homology arms are obtained from a targeting lncRNA genomic locus of a cell, and in some cases, the target genomic locus that the LTVCE is designed to target is not targetable using conventional methods. In yet other embodiments, the homology arms are obtained from synthetic DNA.
[0183] In one embodiment, the upstream homology arm and the downstream homology arm in the LTVEC are at least 10 kb. In another embodiment, the upstream homology arm ranges from about 5 kb to about 100 kb. In one embodiment, the downstream homology arm ranges from about 5 kb to about 100 kb. In another embodiment, the upstream homology arm and the downstream homology arm together are from about 5 kb to about 10 kb, from about 10 kb to about 20 kb, from about 20 kb to about 30 kb, from about 30 kb to about 40 kb, from about 40 kb to about 50 kb, from about 50 kb to about 60 kb, from about 60 kb to about 70 kb, from about 70 kb to about 80 kb, from about 80 kb to about 90 kb, from about 90 kb to about up to 100 kb, about 100 kb to about 110 kb, about 110 kb to about 120 kb, about 120 kb to about 130 kb, about 130 kb to about 140 kb, about 140 kb to about 150 kb, about 150 kb to about 160 kb, about 160 kb to about 170 kb, about 170 kb to about 180 kb, about 180 kb to about 190 kb, or about 190 kb to about 200 kb. In one embodiment, the size of the deletion is the same as or similar to the overall size of the combined 5' and 3' homology arms of the LTVEC.
[0184] In one embodiment, the LTVEC comprises a selection cassette or reporter gene, as discussed elsewhere herein.
[0185] III. Methods for introducing sequences and generation of transgenic animals As outlined above, methods and compositions are provided herein to allow targeted gene modification of one or more lncRNA loci.It is further recognized that additional targeted gene modifications can be made.Such systems that allow these targeted gene modifications can use various components, and for ease of reference, the term "targeted genome integration system" herein generally includes all the components required for integration (i.e., various nuclease factors, recognition sites, insert DNA, polynucleotides, targeting vectors, target genome loci, and polynucleotides of interest).
[0186] The methods provided herein include introducing one or more polynucleotides or polypeptide constructs that include various components of a targeted genome integration system into a cell. "Introducing" means presenting a sequence (polypeptide or polynucleotide) to a cell so that the sequence follows a path to the inside of the cell. The methods provided herein do not depend on the specific method of introducing any component of a targeted genome integration system into a cell, only that the polypeptide follows a path to the inside of the cell. Methods of introducing polynucleotides into various cell types are known in the art and include, but are not limited to, stable transfection methods, transient transfection methods, and virus-mediated methods.
[0187] In some embodiments, the cell used in the method and composition has a DNA construct that is stably incorporated into the genome of the cell. "Stably incorporated" or "stably introduced" means that a polynucleotide is introduced into the cell so that the nucleotide sequence is incorporated into the genome of the cell and can be inherited by the descendants of the cell. Any protocol can be used to stably incorporate the various components or DNA constructs of the targeted genome integration system.
[0188] Transfection protocols, as well as protocols for introducing polypeptide or polynucleotide sequences into cells, may vary widely. Non-limiting transfection methods include chemical-based transfection methods, such as the use of liposomes, nanoparticles, calcium phosphate (Graham et al. (1973), Virology 52(2): 456-67, Bacchetti et al. (1977) Proc Natl Acad Sci USA 74 (4): 1590-4, and Kriegler, M. (1991), Transfer and Expressin: A laboratory Manual. New York: WH Freeman and COmpany. pp. 96-97); dendrimers; or cationic polymers such as DEAE-dextran or polyethyleneimine. Non-chemical methods include electroporation, sono-poration, and optical transfection. Particle-based transfection includes gene guns, magnet-assisted transfection (Bertram, J. (2006) Current Pharmaceutical Biotechnology 7, 277-28. Viral methods can also be used for transfection.
[0189] Non-human animals can be made using various methods disclosed herein. Such methods include: (1) integrating one or more polynucleotides of interest into a target lncRNA genomic locus of interest of a pluripotent cell of a non-human animal to make a genetically modified pluripotent cell containing an insertion polynucleotide in the targeted lncRNA genomic locus using the methods disclosed herein; (2) selecting a genetically modified pluripotent cell having one or more polynucleotides in the target lncRNA genomic locus; (3) introducing the genetically modified pluripotent cell into a host embryo of a non-human animal, for example at the pre-morula stage; and (4) implanting the host embryo containing the genetically modified pluripotent cell into a surrogate mother to make an F0 generation derived from the genetically modified pluripotent cell. Similar methods can be used to target a target chromosomal locus of interest. The non-human animal can be a non-human mammal, a rodent, a mouse, a rat, a hamster, a monkey, an agricultural or domestic mammal, or a fish or a bird.
[0190] The pluripotent cell can be ES cell, mouse ES cell, rat ES cell, hamster ES cell, monkey ES cell, agricultural mammalian ES cell, or livestock mammalian ES cell.In other embodiments, the pluripotent cell is a non-human cell, a mammalian cell, a human cell, a non-human mammalian cell, a human pluripotent cell, a human ES cell, a human adult stem cell, a developmentally restricted human progenitor cell, a human iPS cell, a rodent cell, a rat cell, a mouse cell, or a hamster cell.In one embodiment, the targeted gene modification results in the loss of function of the lncRNA.
[0191] Nuclear transfer techniques can also be used to create non-human animals. Briefly, nuclear transfer methods include (1) enucleating an oocyte, (2) isolating a donor cell or nucleus to be combined with the enucleated oocyte, (3) inserting a cell or nucleus into the enucleated cell to form a reconstituted cell, (4) implanting the reconstituted cell into the uterus of an animal to form an embryo, and (5) allowing the embryo to develop. In such methods, oocytes are generally removed from dead animals, although they can also be isolated from either the oocyte and / or ovary of the animal. The oocytes can be matured in various media known to those skilled in the art prior to enucleation. Inserting a donor cell or nucleus into the enucleated oocyte to form a reconstituted cell is usually performed by microinjection of the donor cell under the zona pellucida prior to fusion. Fusion can be induced by applying a DC electric pulse across the contact / fusion surface (electrofusion), by exposing the cells to fusion-promoting chemicals such as polyethylene glycol, or by using an inactivated virus such as Sendai virus. The reconstituted cells are generally activated by electrical and / or non-electrical means before, during, and / or after fusion of the nuclear donor with the recipient oocyte. Activation methods include electrical pulses, chemically induced shocks, penetration by sperm, increasing the concentration of divalent cations in the oocyte, and decreasing phosphorylation of cellular proteins in the oocyte (as via kinase inhibitors). The activated reconstituted cells, i.e., embryos, are usually cultured in media well known to those skilled in the art and transferred to the uterus of an animal. See, for example, US20080092249, WO / 1999 / 005266A2, US20040177390, WO / 2008 / 017234A1, and U.S. Pat. No. 7,612,250. These Each is incorporated herein by reference.
[0192] Other methods of making a non-human animal comprising one or more genetic modifications described herein in its germline are provided, comprising: (a) modifying a targeted genomic lncRNA locus of the non-human animal in a prokaryotic cell, (b) selecting a modified prokaryotic cell comprising a genetic modification at the targeted genomic locus, (c) isolating a genetically modified targeting vector from the genome of the modified prokaryotic cell, (d) introducing the genetically modified targeting vector into a pluripotent cell of the non-human animal to generate a genetically modified pluripotent cell comprising an insert nucleic acid at the targeted lncRNA genomic locus, (e) selecting the genetically modified pluripotent cell, (f) introducing the genetically modified pluripotent cell into a host embryo of the non-human animal at the pre-morula stage, and (g) implanting the host cell comprising the genetically modified pluripotent cell into a surrogate mother to generate an F0 generation derived from the genetically modified pluripotent cell. In such methods, the targeting vector comprises a large targeting vector. The non-human animal may include a non-human mammal, a rodent, a mouse, a rat, a hamster, a monkey, a farm mammal, or a livestock mammal. The pluripotent cell may be a human ES cell, a non-human ES cell, a rodent ES cell, a mouse ES cell, a rat ES cell, a hamster ES cell, a monkey ES cell, a farm mammal ES cell, or a livestock mammal ES cell. In other embodiments, the pluripotent cell is a non-human cell, a mammalian cell, a human cell, a non-human mammalian cell, a human pluripotent cell, a human ES cell, a human adult stem cell, a developmentally restricted human progenitor cell, a human iPS cell, a human cell, a rodent, a rat cell, a mouse cell, or a hamster cell. In one embodiment, the targeted gene modification results in the loss of function of the lncRNA.
[0193] In a further method, the isolation step (c) further comprises (c1) linearizing the genetically modified targeting vector (i.e., the genetically modified LTVEC). In yet another embodiment, the introduction step (d) further comprises (d1) introducing a nuclease agent into the pluripotent cell to promote homologous recombination. In one embodiment, the selection step (b) and / or (e) may be carried out by applying a selectable agent as described herein to the prokaryotic or pluripotent cell. In one embodiment, the selection step (b) and / or (e) may be carried out via a modification of allele (MOA) assay as described herein.
[0194] In some embodiments, the various genetic modifications of the target genomic loci described herein are synthesized in bacterial cells by a series of homologous recombination reactions (BHR), using VELOCIMOUSE® genetic engineering techniques (see, e.g., U.S. Pat. No. 6,586,251 and Valenzuela, DM et al. (2003), Nature Biotechnology). This can be accomplished using bacterial artificial chromosome (BAC) DNA derived LTVEC using the genomic DNA library (see, J. Immunol. 21(6): 652-659).
[0195] In some embodiments, various genetically modified lncRNA-targeted pluripotent and / or totipotent cells as described herein are used as insert donor cells and introduced into pre-morula stage embryos (e.g., 8-cell stage mouse embryos) from the corresponding organisms via the VELOCIMOUSE® method (see, e.g., US7,576,259, US7,659,442, US7,294,754, and US2008-0078000A1, all of which are incorporated by reference in their entirety). The non-human animal embryos containing the genetically modified pluripotent and / or totipotent cells are incubated to the blastocyst stage and then implanted into a surrogate mother to generate the F0 generation. In some embodiments, targeted mammalian ES cells containing various genetic modifications as described herein are introduced into the blastocyst stage embryos. Non-human animals carrying genetically modified genomic loci (i.e., lncRNA loci) can be identified via modification of alleles (MOA) as described herein. The resulting F0 generation human animals derived from the genetically modified pluripotent and / or totipotent cells are bred with wild-type non-human animals to obtain F1 generation progeny. After genotyping with specific promoters and / or probes, the F1 non-human animals heterozygous for the genetically modified genomic loci are bred with each other to produce F2 generation non-human animal progeny that are homozygous for the genetically modified genomic loci.
[0196] In one embodiment, a method of making a human animal comprising a genetic modification in at least one lncRNA locus is provided, the method comprising: (a) contacting a pluripotent cell with a targeting construct comprising an insert nucleic acid flanked by 5' and 3' homology arms, the targeting construct homologously recombining with a lncRNA locus in the genome of the cell to form a modified pluripotent cell; (b) introducing the modified pluripotent cell into a host embryo; and (c) gestating the host embryo in a surrogate mother, the surrogate mother giving birth to an offspring comprising the modified lncRNA locus, the genetic modification resulting in a loss of function of at least one lncRNA.
[0197] IV.Cells Various methods described herein use a genomic locus targeting system to modify lncRNA loci in cells. Such cells include bacterial cells such as E. coli, yeast, insect, amphibian, plant, eukaryotic cells, including but not limited to mouse cells, rat cells, hamster cells, rabbit cells, pig cells, bovine cells, deer cells, sheep cells, goat cells, chicken cells, cat cells, dog cells, ferret cells, primate (e.g., marmoset, rhesus monkey) cells, and other mammalian cells, as well as domesticated mammalian cells or farmed mammalian cells. Some cells are non-human cells, specifically non-human mammalian cells. In one embodiment, for those mammals for which suitable genetically modifiable pluripotent cells are not readily available, other methods are used to reprogram somatic cells into pluripotent cells. For example, by introducing a combination of pluripotency inducers into somatic cells. These factors include, but are not limited to, Oct3 / 4, Sox2, KLF4, Myc, Nanog, LIN28, and Glis1. In such methods, the cell can be a mammalian cell, a human cell, a non-human mammalian cell, a non-human cell, a cell from a rodent, a rat, a mouse, a hamster, a fibroblast, or any other host cell. In other embodiments, the cell is a pluripotent cell, an induced pluripotent stem (iPS) cell, a non-human embryonic stem (ES) cell. Such cells include pluripotent cells, such as induced pluripotent stem (iPS) cells, human iPS cells, mouse embryonic stem (ES) cells, rat embryonic stem (ES) cells, human embryonic (ES) cells, or developmentally restricted human progenitor cells, rodent embryonic stem (ES) cells, mouse embryonic stem (ES) cells, or rat embryonic stem (ES) cells.
[0198] Non-limiting embodiments include the following:
[0199] 1. A non-human animal, comprising within its genome at least one modified long non-coding RNA (lncRNA) locus, wherein the at least one modified lncRNA locus comprises a loss-of-function mutation in a nucleic acid sequence encoding the lncRNA.
[0200] 2. The non-human animal of embodiment 1, wherein the lncRNA is a long intergenic non-coding RNA (lincRNA).
[0201] 3. The non-human animal of any one of embodiments 1 or 2, wherein the loss-of-function mutation is characterized by the disruption or knockout of at least one lncRNA function.
[0202] 4. The non-human animal of embodiment 3, wherein the modified lncRNA locus comprises a deletion of one or more exons encoding the lncRNA or a portion thereof.
[0203] 5. The non-human animal of embodiment 4, wherein the disruption or knockout comprises: (a) a deletion of one or more exons in the lncRNA gene starting within the second exon of the lncRNA locus; (b) a deletion of one or more exons in the lncRNA locus starting within the first exon of the lncRNA locus; or (c) a deletion of the entire RNA coding region of the lncRNA locus.
[0204] 6. The non-human animal of embodiment 3, wherein the disruption or knockout comprises replacing the lncRNA locus or a portion thereof with an inserted nucleic acid.
[0205] 7. The genetically modified non-human animal of embodiment 6, wherein the insert nucleic acid comprises a first nucleotide sequence encoding a reporter.
[0206] 8. The genetically modified non-human animal of embodiment 7, wherein the first nucleotide sequence is operably linked to a promoter that drives expression of the reporter.
[0207] 9. The genetically modified non-human animal of embodiment 7, wherein the first nucleotide sequence encoding the reporter is located within a lncRNA locus operably linked to an endogenous lncRNA promoter, and the endogenous lncRNA promoter drives expression of the nucleotide sequence.
[0208] 10. The non-human animal of embodiment 9, wherein expression of the nucleic acid sequence follows an expression pattern of the lncRNA.
[0209] 11. The genetically modified non-human animal of embodiment 7, wherein the first nucleotide sequence comprises a Kozak consensus sequence.
[0210] 12. The non-human animal of any one of embodiments 6-11, wherein the replacement comprises (a) replacing one or more exons in the lncRNA locus starting within the second exon of the lncRNA locus with the insert nucleic acid, (b) re-replacing one or more exons in the lncRNA locus starting within the first exon of the lncRNA locus with the insert nucleic acid, or (c) replacing the entire RNA coding region of the lncRNA locus with the insert nucleic acid.
[0211] 13. The non-human animal of any one of embodiments 6-12, wherein the reporter is any of β-galactosidase, green fluorescent protein (GFP), enhanced green fluorescent protein (eGFP), mPlum, mCherry, tdTomato, mStrawberry, J-Red, DsRed, mOrange, mKO, mCitrine, Venus, YPet, enhanced yellow fluorescent protein (EYFP), Emerald, CyPet, cyan fluorescent protein (CFP), Cerulean, T-Sapphire, luciferase, alkaline phosphatase, or a combination thereof.
[0212] 14. The non-human animal of any one of embodiments 6 to 13, wherein the insert nucleic acid further comprises a second nucleic acid sequence encoding a selectable marker, the second nucleic acid sequence being operably linked to a promoter.
[0213] 15. The non-human animal of embodiment 14, wherein the insert nucleic acid comprises site-specific recombination sites flanking the segment encoding the reporter and / or the segment encoding the selectable marker.
[0214] 16. The non-human animal of any one of embodiments 1-15, wherein the lncRNA comprises Pint, Celrr, Crnde, Eldr, Fendrr, Halr1, Hotair, HOTTIP, Hoxa11os, Pantr1, Pantr2, Ptgs2os2, lincenc1, Trp53cor1, lincppara, Mannr, Haglr, Peril, Kantr, Tug1, or a combination thereof.
[0215] 17. The non-human animal of any one of embodiments 1-16, wherein the non-human animal is characterized by having one or more of the following phenotypes: (a) a premature aging-associated phenotype; (b) perinatal lethality; (c) defects in lung development; (d) morphological malformations of the tail and hind limbs; (e) loss of muscle mass in one or more tissues; or (f) any combination thereof (a)-(e).
[0216] 18. The non-human animal of embodiment 1, wherein the lncRNA is Pint, and the human animal is characterized by premature aging-associated phenotypes including: (a) slower growth rate than wild-type controls; (b) reduced muscle strength; (c) fibrosis; (d) lower body fat content than wild-type controls; (e) lower femoral bone mineral density and bone mass than wild-type controls; (f) reduced muscle mass compared to wild-type controls; (g) reduced median life span; (h) spinal curvature; (i) organ atrophy; or (j) any combination thereof of (a)-(i).
[0217] 19. The non-human animal of any one of embodiments 1-15, wherein the non-human animal exhibits defects in brain development.
[0218] 20. The non-human animal of embodiment 19, wherein the lncRNA is Pantr2, Kantr, Peril, Celrr, Pantr1, Crnde, lincenc1, Pint, lincppara, or Tug1.
[0219] 21. The genetically modified non-human animal of any one of embodiments 1 to 20, wherein the human animal is a mammal.
[0220] 22. The genetically modified non-human animal of embodiment 21, wherein the mammal is a rodent.
[0221] 23. The genetically modified non-human animal of embodiment 22, wherein the mammal is a mouse, a rat, or a hamster.
[0222] 24. A cell, tissue, or embryo derived from a non-human animal of any one of embodiments 1 to 23.
[0223] 25. A targeting vector comprising an insert nucleic acid flanked by 5' and 3' homology arms capable of homologous recombination with a lncRNA locus of interest.
[0224] 26. The targeting vector of embodiment 25, wherein the insert nucleic acid comprises a first nucleic acid sequence encoding a reporter.
[0225] 27. The targeting vector of embodiment 26, wherein a first nucleic acid sequence encoding a reporter is operably linked to an endogenous promoter that drives expression of a lncRNA at the lncRNA locus following homologous recombination with the lncRNA locus of interest.
[0226] 28. The targeting vector of any one of embodiments 26-27, wherein the reporter is any of β-galactosidase, green fluorescent protein (GFP), enhanced green fluorescent protein (eGFP), mPlum, mCherry, tdTomato, mStrawberry, J-Red, DsRed, mOrange, mKO, mCitrine, Venus, YPet, enhanced yellow fluorescent protein (EYFP), Emerald, CyPet, cyan fluorescent protein (CFP), Cerulean, T-Sapphire, luciferase, alkaline phosphatase, or a combination thereof.
[0227] 29. The targeting vector construct of embodiments 25 to 28, wherein the insert nucleic acid further comprises a second nucleic acid sequence encoding a selectable marker, the second nucleic acid being operably linked to a promoter.
[0228] 30. The targeting vector of embodiment 29, further comprising site-specific recombination sites flanking the segment encoding the reporter and / or the segment encoding the nucleic acid of a selectable marker.
[0229] 31. The targeting vector of any one of embodiments 26 or 29, wherein the first nucleic acid sequence and / or the second nucleic acid sequence further comprises a Kozak consensus sequence.
[0230] 32. The targeting vector of any one of embodiments 25-31, wherein the insert nucleic acid further comprises a promoter driving expression of the reporter.
[0231] 33. A method for generating a human animal comprising a genetic modification in at least one lncRNA locus, the method comprising: (a) contacting a pluripotent cell with a targeting construct comprising an insert nucleic acid flanked by a 5' homology arm and a 3' homology arm, whereby the targeting construct undergoes homologous recombination with the lncRNA locus in the cell to form a modified pluripotent cell; (b) introducing the modified pluripotent cell into a host embryo; and (c) gestating the host embryo in a surrogate mother, whereby the surrogate mother gives birth to offspring comprising the modified lncRNA locus, wherein the genetic modification results in a loss of function of at least one lncRNA.
[0232] 34. The method of embodiment 33, wherein the lncRNA is a lincRNA.
[0233] 35. The method of embodiments 33-34, wherein the genetic modification comprises disruption or knockout of at least one lncRNA function.
[0234] 36. The method of any one of embodiments 33 to 35, wherein the lncRNA comprises Pint, Celrr, Crnde, Eldr, Fendrr, Halr1, Hotair, HOTTIP, Hoxa11os, Pantr1, Pantr2, Ptgs2os2, lincenc1, Trp53cor1, lincppara, Mannr, Haglr, Peril, Kantr, Tug1, or a combination thereof.
[0235] 37. A method for modifying a lncRNA locus in a pluripotent cell, comprising: (a) introducing into the pluripotent cell a targeting construct comprising an insert nucleic acid flanked by 5' and 3' homology arms capable of undergoing homologous recombination with a lncRNA locus in the genome of the cell; and (b) identifying a modified pluripotent cell comprising a targeted genetic modification at the lncRNA locus, wherein the genetic modification results in a loss-of-function of the lncRNA function.
[0236] 38. The method of embodiment 37, wherein the pluripotent cells are human iPS cells.
[0237] 39. The method of embodiment 37, wherein the pluripotent cells are mouse or rat embryonic stem (ES) cells.
[0238] 40. The method of any one of embodiments 37-39, wherein the lncRNA comprises Pint, Celrr, Crnde, Eldr, Fendrr, Halr1, Hotair, HOTTIP, Hoxa11os, Pantr1, Pantr2, Ptgs2os2, lincenc1, Trp53cor1, lincppara, Mannr, Haglr, Peril, Kantr, Tug1, or a combination thereof.
[0239] 41. A genetically altered non-human animal, wherein the genetic modification comprises a knockout of Pint.
[0240] 42. The genetically modified non-human animal of Example 41, which is a rodent.
[0241] 43. The genetically modified rodent of example 42, wherein the rodent is selected from a mouse and a rat.
[0242] 44. Mice exhibiting premature aging-associated phenotypes, including knockout of Pint.
[0243] 45. The mouse of Example 44, wherein the mouse exhibits a phenotype selected from slow weight gain, earlier plateauing weight, early growth arrest, spinal curvature by 12 weeks of age, severe spinal curvature by 26 weeks of age, loss of fur at around 6 months of age, loss of hind limb strength at around 6 months of age, and combinations thereof.
[0244] 46. A genetically modified non-human animal comprising a knockout of a lncRNA selected from the group consisting of HOTAIR, HOTTIP, Hoxa11os, Pantr1, Pantr2, Ptgs2os2, Eldr, Lincenc1, Mannr, Fendrr, Halr1, Haglr, Celrr, Crnde, Kantr, Pint, Trp53cor1, lincppara, Haglr, Tug1, and combinations thereof.
[0245] 47. The genetically modified mouse of embodiment 46, which is a rodent.
[0246] 48. The genetically modified rodent of embodiment 47, which is a mouse or a rat. EXAMPLES
[0247] Example 1: Construction of a targeting vector As previously described, the VelociGene® method was used, which allows for rapid and high-throughput generation of custom gene mutations in mice (Valenzuela, D. M. et al., (2003b), Nat Biotchnol 21:652-659). Specifically, BacVec large targeting vectors (LTVEC) were generated using BAC clones derived from mouse bMQ (129S7 / SvEv Brd-Hprt b-m2) or RP23 BAC libraries (Adams, DJ et al. (2005), Genomics 86:753-758). r The reporter / selection cassette (Figure 1) is identical to the ZEN-Ub1 cassette utilized in NIH KOMP (sequence available at www.velocigene.com / komp / detail / 10020.) except that the amino terminus of the β-galactosidase portion of the lacZ fragment has been modified to contain an ATG start codon and a Kozak consensus sequence (Kozak, M. (1987) nucleic acids research 15:8125-8148). It was identical to the previous one.
[0248] Example 2: ES cell targeting LTVEC is 3.3 x 10 6 Cells, 0.67 μg DNA, in a volume of 0.125 ml of electroporation buffer (Millipore) were transfected into VGF1 hybrid (129S6SvEvTAc / C57BL6NTac) ES cells (Poueymirou et al., 2007; Valenzuela et al., 2003a) using a multiwell electroporation apparatus (Harvard Apparatus, Boston, MA). After electroporation, the cells were cultured on 15 cm gelatin-coated plates. Selection medium containing G418 was added 48 hours after electroporation and changed daily thereafter. Drug-resistant colonies were picked 10 days after electroporation and cultured on gelatin-coated 96-well plates for at least 3 days before DNA extraction and purification. Allelic deletion assay (Frendewey et al., (2010), Methods i enzymology 476:295-301: Valenzuela et al. (2003a), Nat. Biotechnol. 21:652-659) Identified.
[0249] Example 3: Generation of lincRNA mice The VelociMouse® method (Dechiara, TM, (2009), Methods Mol Biol 530-311-324: Poueymirou et al., (2007), Nat. Biotechnol. 25:91-99) was used, in which targeted ES cells were injected into uncompacted 8-cell Swiss Webster embryos to generate F0 generation mice entirely derived from ES cells carrying lincRNA knockout mutations. Male VelociMouse® were used directly for lacZ expression profiling or mated with C57BL / 6NTac females to generate embryos or adults for LacZ analysis or to generate F1 breeders and phenotypic studies were performed in N2F1 mice. Timed mating was performed by setting the morning when a vaginal plug was observed as day 0.5 (E0.5).
[0250] Example 4: LacZ Expression Profiling For whole-mount staining, E9.5 and E14.5 embryos were collected, stained in PBS, and incubated in fresh 0.2% glutaraldehyde solution for 15–60 min. Yolk sacs were harvested for genotyping. After fixation, embryos were washed in washing buffer and incubated in X-gal (1 mg / mL) at 37°C for 1–24 h. After staining, tissues were rinsed in washing buffer, post-fixed in 4% paraformaldehyde, and incubated in 70% ethanol for at least 24 h. E9.5–e11.5 embryos were photographed immediately, whereas e12.5 embryos and older were cleared in a series of solutions containing increasing amounts of glycerol and decreasing amounts of 1% KOH in ddH2O. Photographs were taken using a Nikon SMZ800 stereomicroscope. Embryos from Fendrr e13.5 embryos were dissected for photographs after clearing.
[0251] For studies using adult mice, 6-8 week old VelociMice®, entirely derived from F0 generation ES cells, were deeply anesthetized and fixed by cardiac perfusion with 0.2% glutaraldehyde / 4% paraformaldehyde solution. Tissues of the brain, thorax, heart, lungs, liver, spleen, stomach, kidneys, intestines, urogenital tract, muscle, and hind limbs were dissected, rinsed with PBS, and post-fixed for 30 minutes in 0.2% glutaraldehyde / 4% paraformaldehyde solution. Tissues were then washed and incubated at 37°C for 1-24 hours in X-gal (1 mg / mL) staining solution. After staining, tissues were rinsed with washing buffer, post-fixed with 4% paraformaldehyde, cleared in a series of 50%, 70%, and 100% glycerol, and photographed as for embryos.
[0252] Example 5: Animal care and experimental procedures Phenotyping of N2F1 mice was initiated at 6-8 weeks of age. Timed mating was performed with embryonic day 0.5 (E0.5) defined as the morning a vaginal plug was observed. lincRNA KO and wild-type littermates were housed at 69-74°F, 40-60% humidity, and 12 hours of light per day for the study and observed for various developmental milestones (reduced growth, respiration, facial and limb abnormalities, skin color, posture, righting, and eye opening) from birth until approximately 6-8 weeks of age. All experiments were initiated at approximately 6-8 weeks of age, and all animal procedures were performed in accordance with protocols approved by the Regeneron Pharmaceuticals Institutional Animal Care and Use Committee.
[0253] Experiment 6: μCT analysis 3D skeletal imaging visualization was performed using a Quantum FX microCT preclinical in vivo imaging system (Perkin Elmer). Mice were anesthetized using oxygen / isofuran inhalation with an isofluorane flow rate of 2.5 L / min and oxygen flow rate of 1.5 L / min. Anesthesia was maintained with an oxygen inflow rate of 0.25 L / min through a nose cone during the scanning process. Anesthesia was maintained. Scans were performed at 90 kV and 160 μA with a 30 mm field of view for the hind limbs and a 60 mm field of view for the spine. Bone mineral density, total bone mass, and lean and fat mass were measured. For analysis of bone mineral density, two consecutive scans were performed with a 60 mm field of view on the whole body, excluding the head. The right thigh was manually separated to measure bone mineral density. All lean and fat masses of the right thigh were measured using Analyze 11.0 software (Mayo Clinic) and converted to mass based on set density. After scanning, mice were returned to their cages and monitored for recovery according to Regeneron IACUC protocols.
[0254] Example 7: Tail suspension test During tail suspension, mice spread their hindlimbs (often referred to as "hindlimb splay") in preparation for a safe landing. Mice were suspended by their tails for 10 seconds and observed for any abnormal grasping phenotypes.
[0255] Example 8: Grasping Duration Test Mice were evaluated at 5, 7, and 10 weeks of age for signs of muscle damage by their ability to hang upside down from a wire grid (approximately 2 mm wire thickness). Mice were individually placed on the wire grid, which was gently shaken to allow the mouse to grasp the grid as it inverted. The time it took for the mouse to let go (up to a maximum of 60 seconds) was recorded. Mice were given three attempts to hold on as long as possible, and the maximum time was recorded for statistical comparison.
[0256] Example 9: Muscle Histology and Tissue Autopsy Mice were euthanized by CO2 inhalation followed by cervical dislocation. Tibialis anterior (TA), quadriceps, and gastrocnemius (GA) muscles were excised and weighed. All collected muscles and organs were frozen and kept at -80°C for future examination. For histology, muscles were frozen in OCT and cryosectioned obliquely at 12 μm thickness to expose the lateral and medial heads, soleus, and plantaris muscles. Adjacent sections were stained with H&E, lamin, and MHC Slow Stain. The stains were digitally imaged using an Aperio Scanscope. Fiber size and counts were determined using Spectra software. All data were expressed as mean ± standard error (shown by error bars). Analysis of variance (ANOVA) was performed using the programs STATVIEW and / or PRISM. Statistical significance was set at a P value of less than 0.05. For skin histology, dorsal and ventral skin areas were shaved, excised, fixed in 4% paraformaldehyde (PFA) for at least 24 hours, and transferred to 70% ethanol. Paraffin embedding, sectioning, and hematoxylin and eosin staining of skin sections were performed by Histoserv Labs, Inc., Germanton, MD.
[0257] Example 10: Kaplam-Meier survival curve analysis Animals were observed for 52 weeks and monitored for signs of morbidity according to Regeneron IACUC protocols. Mice in this study were not required to be sacrificed prior to the 52-week time point based on morbidity guidelines. Survival curves and log-rank tests were determined using Graphpad PRISM 6 software.
[0258] Example 11: Diverse phenotypes and specific transcription patterns in 20 mouse strains harboring truncated lncRNAs In a survey of 20 knockout mouse lines designed to investigate the biological functions of long intergenic noncoding RNAs (lincRNAs), we found a range of phenotypes ranging from perinatal lethality to premature aging-associated defects and morphological and functional abnormalities in lung, skeleton, and muscle. Each mutant allele carries a lacZ reporter, whose expression profiles highlight widespread spatiotemporal and tissue-specific transcriptional patterns in embryos and adults that inform our phenotypic analysis and will serve as a guide for future investigations of these genes. Our studies demonstrate that lincRNAs are a novel class of encoded molecules that, like proteins, play essential and critical functional roles in embryonic development, physiology, and homeostasis of a wide range of mammalian tissues and organs.
[0259] More recently, it has become clear that a thorough understanding of mammalian genotype-phenotype relationships requires us to expand our studies beyond protein-coding genes to include non-coding portions of the genome (Mattick JS (2009) PLos genetics 5:e1000459). Large-scale whole-genome expression studies in mammalian cells have demonstrated that approximately 3 / 4 of the genome is expressible as RNA (Kapranov P et al. (2007) Science 316: 1484-1488; Carninci P et al. (2005) Science 309: 1559-1563; Djebali S et al. (2012) Nature 489: 1-1-108) and that most of the transcripts do not code for proteins. Non-coding transcripts include a diverse class of RNA known as long non-coding RNAs (lncRNAs). Approximately 15,000 transcripts from approximately 10,000 genomic loci in human cells are represented (Derrien T et al. (2012) Genome Research 22: 1775-1789), and a subclass of RNA known as lncRNAs and long intergenic non-coding RNAs (lincRNAs) (Guttman M et al. (2009) Nature 458: 223-227; Khalil AM et al. (2009) Proceedings of the National Academy of Sciences of the United States of America 106: 11667-11672) resemble protein-coding mRNAs in terms of structure, synthesis, and chromatin properties of genes. Whether this structural similarity extends to a functional diversity that matches the functional diversity of proteins remains an open question.
[0260] Since the creation of the first knockout strains nearly 25 years ago, the mouse has become the most important system for the study of mammalian gene function (Capecchi MR (2001) Nat Med 7: 1086-1090; Evans MJ (2001) Nat Med 7: 1081-1083; Smithies O (2001) Nat Med 7: 1083-1086). With a few exceptions, the application of knockout mouse technology in individual gene studies or large international projects (www.knockoutmouse.org) has focused on protein-coding genes, but recent efforts to create a universal knockout mouse resource for microRNAs (Prosser HM et al. (2011) Nature Biotechnology 29:840-845) (mcmanuslab.ucsf / microrna_knockout) show that there is value in applying such techniques to non-coding RNAs. Although there have been some functional studies of individual lncRNAs by gene disruption in mice, about half have focused on single, well-studied lncRNAs involved in related biological phenomena. That is, such a phenomenon is X-chromosome inactivation (Marhrens Y et al. (1997) G Genes & Development 11:156-166; Sado T et al. (2001) Development 128: 1275-1286), and somatic chromosomal imprinting (Leighton PA et al. (1995) Nature 375: 34-39; Mohammad F et al. (2010) Developm ent 137: 2493-2499; Sleutels FF et al. (2002) Nature 415: 810-813; Takahashi N et al. (2009) Human Molecular Generics 18: 1879-1888).
[0261] Recently, disruption of the mouse Fendrr lncRNA resulted in embryonic lethality associated with defects in heart and body wall development (Grote P et al., (2013) Developmental Cell 24: 206-214). However, deletion or insertion mutations in the lncRNA-encoding Gt(ROSA)26Sor (Zambrowicz BP et al., (1997) Proceedings of the National Academy of Sciences) led to embryonic lethality associated with defects in heart and body wall development (Grote P et al., (2013) Developmental Cell 24: 206-214). of Sciences of the United States of America 94: 3789-3794) or Malat1 (Zhang B et al. (2012) Cell Reports 2: 111-123) Genes are recognized The newly gained knowledge of lncRNA gene structure, expression, and function represents a new opportunity to use mouse molecular genetics to uncover biological functions associated with this novel class of genes.
[0262] However, applying knockout mouse technology to lncRNAs presents several technical challenges. Most proteins have elements or domains that are known or at least predicted to be functionally relevant. Deleting the coding sequence of these essential parts is often sufficient to create a null allele. Similarly, conditional alleles can be designed that isolate an exon or exons that are important for subsequent deletion by the action of tissue-specific recombinases. Structure-function relationships have yet to be established for all but a few lncRNAs, and the absence of open reading frames as a guide suggests that knockout strategies available for protein-coding genes are not applicable to genomic loci that code for lncRNAs. Despite improvements in the annotation of lncRNA genes (Derrien T et al., (2012) Genome Research 22: 1775-1789), the exact boundaries of some genes may still remain unclear, which may make knockout allele design difficult. A powerful tool applied to knockout mice of protein-coding genes is the replacement of the target gene with a reporter (e.g., coding sequence for β-galactosidase or a fluorescent protein), whose expression is controlled by the promoter of the target gene, thereby reporting the spatiotemporal pattern of expression in mice. Reporter gene replacement was performed by detecting the lncRNA-encoding Gt(ROSA)26Sor locus (Zambrowicz BP et al., (1997) Proceedings of the National Academy of Sciences of It has been successfully applied to non-coding RNAs such as genes encoding lncRNAs (Thai TH et al., (2007) Science 316: 604-608) and the small non-coding RNA miR-155 (Thai TH et al., (2007) Science 316: 604-608). However, it appears necessary to develop rules for creating such alleles of lncRNAs. Despite these limitations, with thousands of identified lncRNAs, the time is ripe to explore the application of the power of knockout mouse technology to this new class of genes. With this objective in mind, we describe herein an integrated genetic approach to define 20 lincRNAs by creating knockout mouse lines, each carrying a gene ablation deletion allele with β-galactosidase reporter substitution.
[0263] Generation of 20 lincRNA-deficient mouse strains by reporter gene replacement Table 1 lists the 20 lincRNAs on 10 different chromosomes that were targeted in this study and the 26 knockout deletion alleles that were created. We chose members of the long intergenic noncoding RNA class for mutations because, by definition, lincRNA genes are isolated from adjacent protein-coding genes and their transcripts do not overlap (Guttman et al. (2009) Nature 458: 223-227). This feature allowed us to design deletion alleles that would at least have the potential to be interfered with by the expression of neighboring genes. We focused on neural expression and the target lincRNA genes were selected to reflect different expression patterns due to their potential involvement in development and regulation of gene expression (Khalil AM et al. (2009) Proceedings of the National Academy of Sciences of the United States of America 106: 11667-11672; Cabili MN et al. (2011) Genes & Development 25: 1915-1927).
[0264] Our design strategy for lincRNA knockout mutations was guided by two objectives. First, we aimed to create alleles that actually report on the transcriptional activity of the lincRNA gene. Despite evidence from cell-based and selected tissue dissection studies of tissue-specific lincRNA expression (Cabili MN et al. (2011) Genes & Development 25: 1915-1927), we wanted to complement this knowledge base by generating fine-grained expression patterns afforded by lacZ expression profiling. This could spatially and temporally resolve tissue and organ expression, revealing subdomains and, in some cases, cell type characteristics not resolved by tissue dissection experiments. Second, we sought to create gene ablation deletions that abolished lincRNA synthesis and function in such a way that any phenotypes associated with the mutations would be informative about the critical function of the targeted RNA.
[0265] The size of the knockout deletions ranged from approximately 400 bp to 50 kb, and all of the half-annotated exons were missing. In most of the remaining alleles, the deletion began in the second exon. The application of the VelociGene® method (Valenzuela, DM et al. (2003a), Nat Biotechnol 21: 652-659) for the construction and use of large targeting vectors based on bacterial artificial chromosomes (LTVEC) was key in enabling us to construct the large gene ablation deletions required to ensure null alleles of this new class of high molecular weight functional RNAs.
[0266] Little is known about the interrelationship between the structure and function of the lincNA gene that can guide allele design. Experiments with disruption of the Gt(ROSA)26Sor (Zambrowicz BP et al. (1997) Proceedings of the National Academy of Sciences of the United States of America 94: 3789-3794) and BIC (MiR-155) (Thai TH et al. (2007) Science 316: 604-608) genes have demonstrated that deletions and insertions after the first exon can result in reliable tissue-specific expression of β-galactosidase or other reporters. However, this strategy may fail to achieve a complete null mutation if the fusion transcript derived from the modified allele retains the functional portion of lincrNA from the 5' portion encoded in the first exon (Tsai, MC et al. (2010) Sc ience 329, 689-693). Thus, the knockout allele design shown in Table 1 was a compromise between the desire for a complete ablation mutation with the highest probability of disrupting lncRNA function and the goal of creating alleles that produced accurate and informative gene expression profiles from the β-galactosidase receptor. For example, for the HOTAIR gene, we created two alleles, one lacking near the entire RNA coding sequence and the other with a deletion beginning in the second exon. Both alleles produced identical phenotypes (see below), but only the second one functioned as a reporter of gene expression.
[0267] For lincRNAs that are in close proximity to protein-coding genes and may share divergent promoters, we avoided the possibility of disrupting transcription of neighboring genes by placing the deletion start point within the second exon. Figure 1 shows one such example for the Fendrr gene. The diagram shows an example of design elements common to all alleles: a targeted deletion of all or most of the lincRNA coding sequence, as well as a cassette containing sequences of the E. coli lacZ gene encoding β-galactosidase and a cassette expressing neomycin phosphotransferase (neomycin) for selection of G418-resistant ES cell colonies. r ) for the β-galactosidase reporter. LoxP recombinase recognition sites flank the drug selection cassette, allowing Cre-mediated excision prior to phenotypic analysis. Since there is no functional open reading to which to fuse the LacZ sequence, each allele may have an initiation codon and a Kozak consensus sequence (Kozak, M. (1987), Nucleic Acids Res 15, 8125-8148) for efficient translation of the β-galactosidase reporter.
[0268] Specific and diverse lincRNA gene expression patterns revealed by LacZ reporter profiling To investigate the expression patterns of the 20 target lincRNA genes, X-gal staining for β-galactosidase activity was applied to whole embryos or whole mount tissues and organs of adult mice. The target lincRNA genes showed a variety of unique reporter gene expression patterns (Table 2 in Figure 11) and represented most of the major organ systems and tissue types. For example, in adult tissues, expression of Pantr2, Kantr, and Peril was restricted to the brain. Mannr and Fendrr were expressed in the lung, Eldr was expressed in the urogenital system, and Halr1 was expressed in the thorax. One lincRNA gene, Pint, showed ubiquitous expression in all tissues. We did not detect expression of Hotair, Ptgs2os2, and Haglr genes in any of the adult tissues examined.
[0269] Embryonic expression appears to be a common feature among lincRNAs. Examination of β-galactosidase reporter expression in heterozygous embryos at or around embryonic day 12.5 (E12.5) revealed various specific patterns of 20 target lincRNA genes (Table 2 in Figure 11, Figure 2A). Expression profiles ranged from ubiquitous (Tug1) to highly restricted (e.g., epidermis for Elder, whisker placode for Trp53cor1 (Figure 9), or mammary bud for lincenc1 (Figure 9)). The spatiotemporal patterns of differential spread of limb bud and tail expression of HOTTIP and Hoxa11os are quite similar to those reported for adjacent protein-coding genes in the HoxA cluster (Hostikka, SL, and Capecchi, MR (1998), Mechanisms of Development 70:133-145; Lu, P. et al. (2008), Develop pment135:1395-1405). The expression of Hotair in the posterior tail bud and genital tubercle observed for the β-galactosidase reporter was identical to that determined by in situ hybridization (Schorderet, P. and Double, D. (2011), PLoS Genet 7:21002071). Analysis of β-galactosidase by X-gal staining at different times of embryonic development showed that a portion of the lincRNA genes started expressing early at a restricted site and later spread beyond this early locus (Figure 2B), again reminiscent of Hox protein expression (Nagy, A (2003) Manipulation the mouse embryo: a laboratory mannual, 3rd ed. Cold Spring Harbor, NY, Cold Spring Hobor LAboratory Press. ). For example, expression of HOTTIP and Hoxa11os was initiated far posteriorly in the E9.5 embryo and then extended into the limb bud at a later time, whereas initial expression of Celrr at E9.5 near the anterior end of the embryo was maintained over the next 2 days and extended into the neural tube.
[0270] Consistent with the frequent brain expression seen among human tissue-specific lncRNAs (Derrien T et al. (2012) Genome Research 22: 1775-1789), we found that half of the 20 targeted mouse lincRNA genes were transcriptionally active in the adult brain. Similar to embryonic lincRNA expression, the brain patterns (Figure 3) were unique and varied from ubiquitous (lincppara and Pint) to highly restricted to specific brain structures (Peril, Crnde, and Kantr).
[0271] Age-correlated distinct increase in expression of Pint leads to senescence-like phenotypes Among the 20 targeted lincRNA genes, only Pint showed a global systemic expression pattern, which was mainly restricted to postnatal periods (Table 2 in Figure 11). Unique to Pint is the observed age-related increase in expression (Figure 4). In day 3 neonates, Pint transcriptional activity was low (brain) or undetectable (thoracic muscle), but gradually increased in 3-week-old mice, becoming strong and ubiquitous by day 8. The intensity and timing of Pint expression varied in different organs and tissues, but the general trend was a steady increase in expression after birth, which plateaued in adulthood. To our knowledge, the dynamic expression pattern with age is novel. We have not observed a similar profile in lacZ profiling experiments of hundreds of protein-coding gene knockouts (Valenzuela DM et al. (2003) Nature Biotechnology 21: 652-659).
[0272] The striking age-related increase in whole-body Pint expression revealed by lacZ profiling (Figure 4) suggested a global homeostatic role for Pint in maintaining normal health as mice age. To test this hypothesis, we bred Pint knockout mice homozygously and homozygous (Pint - / - ) mice were treated with wild-type (W T) and heterozygous (Pint + / - ) A follow-up study comparing the animals to a litter-matched control group was conducted. Pint - / - Mice appeared healthy and normal at birth. However, by the age of 3 months, they began to show signs of an early-onset aging-like phenotype. - / - Both mice showed a slower growth rate compared to their WT littermates, but this was more pronounced in males (Figure 5A). - / - Mau The new model is over 30% lighter than the Pint + / -Mice were WT littermates The female Pinto was 15% lighter than the male. - / - Mice were 27% lighter ( (Data not shown). Kaplan-Meier analysis comparing homozygous to heterozygous and WT male mice (Fig. 5B) indicated that loss of Pint was associated with poor survival outcomes. We found no signs of tumors or damage in mutant mice with aging. However, some Pint - / - Mice developed hernia formation, including protrusion of the thoracic xiphoid process associated with thinning of the abdominal wall (data not shown). There was an age-dependent hindlimb clasping posture when mice were tail-suspended (data not shown). The severity of this phenotype varied, but its frequency increased progressively with age, suggesting muscle weakness (see Figure 8 for another example of a HOTTIP knockout line). We also observed loss of fur in both male and female mice (data not shown). Pint - / - Histological analysis of skin sections taken from the ventral and dorsal body of the mice revealed fibrosis and striking differences in hair follicle development accompanied by a dramatic reduction in the thickness of the subcutaneous fat layer (Figure 5C).
[0273] Non-invasive whole-body analysis by microCT of individual mice with aging revealed that Pint - / - Male (Fig. 5D) and female (Fig. 5E) mice showed significantly lower fat content. Loss of total body fat was probably the main contributor to the age-related weight loss (Fig. 5A). - / - Mice also showed significantly higher IFN-γ levels than WT mice. All mice had significantly lower femoral bone mineral density (Figure 5F and Figure 5G). Male mice had significantly reduced lean mass at 52 weeks of age. Both males and females had significantly reduced muscle mass in the gastrocnemius complex (GA) and tibialis anterior (TA), with such reduction beginning at 26 weeks of age. Skeletal imaging showed no significant difference in femoral bone mineral density in male or female Pinto mice compared to WT. - / - Both mice The appearance of severe spinal curvature was evident (Figure 5H). - / -Approximately 70% of the mice showed spinal curvature, compared with 100% at 52 weeks of age (Figure 5I). In contrast, only 10–20% of 26-week-old WT mice showed mild spinal curvature, and this frequency did not increase with age. - / - Mice were kept in a 4-day, 5-day, 10-day, 15-day, 20-day, They did not develop significant spinal curvature, indicating abnormal age-dependent haploinsufficiency of Pint. The range of age-related symptoms in Pint knockout mice suggests that Pint is important for maintaining health and avoiding premature aging during the normal life span of mice.
[0274] Deletion of Fendrr results in perinatal lethality as a result of respiratory distress. Among 20 lincRNA knockout mouse strains, Peril - / - and Fe ndrr - / - Mice showed perinatal lethality. Our Fendrr knockout allele The offspring carry a 26 kb deletion from exon 2 to the last annotated exon (Figure 1). X-gal staining of E12.5 homozygous embryos showed lacZ expression in the frontonasal process, upper airway, lungs, and posterior aorta-gonad-mesonephros (AGM) region (Figure 6A), which was identical in both heterozygous (not shown) and homozygous embryos, indicating highly normal organogenesis. Observation of the developing lungs alone at E13.5 revealed defects in the knockout embryos. The lungs were small and the lobes were globular and disorganized (Figure 6B). Mice homozygous for the Fendrr deletion survived to birth but died shortly after with obvious respiratory problems. The Fendrr mutant perinatal lethal phenotype was the same in mice of two different genetic backgrounds, namely the C57BL6 / 129 hybrid reported here and in mice further backcrossed to C57BL / 6, which poses additional husbandry problems (Sauvageau M et al. (2013) Elife 2: e01749).
[0275] Deletion of Hotair and HOTTIP results in morphological and functional defects in the skeleton and muscle. Embryonic X-gal staining of Hotair and HOTTIP genes showed that their expression is restricted to the posterior and distal limb buds (Figure 2A). In line with these developmentally restricted expression patterns, deletion of Hotair and HOTTIP genes resulted in morphological malformations in the tail and hind limbs of adult mice. - / - In the mouse We observed clear homeotic transfection of the fourth caudal vertebra, which became anatomically similar to the third caudal vertebra (Figure 7). - / - mouse showed abnormal hindlimb grasping posture compared to wild-type littermates (Figure 8A). This behavioral abnormality was accompanied by a loss of grasping endurance as measured by a test in which the mouse remained suspended in an inverted wire cage. Wild-type and HOTTIP mice + / - Mutants hold the grip for approximately 1 min, whereas their homozygous littermates cease gripping within 10–20 s (Fig. 8B). This apparent reduction in grip strength is associated with a loss of muscle mass in the gastrocnemius, but not in the tibialis anterior or quadriceps (Fig. 8C). We observed an approximately 40% reduction in the number of fibers in the gastrocnemius, but not in their average size (Fig. 8D and E). In addition to the muscle defects in HOTTIP knockout mice, we also observed hindlimb skeletal malformations, namely a reduction in the length of the hindlimb calcaneus (Fig. 10).
[0276] The past few years have seen an explosion in our understanding of the non-protein-coding components of the genome, especially in mammals. In addition to long-understood classes of non-coding functional RNAs such as ribosomal RNAs, transfer RNAs, small nuclear RNAs, small nucleolar RNAs, small cytoplasmic RNAs, RNase P, RNAse MRP, and the RNA components of the telomerase enzyme, as well as the more recently discovered microRNAs and PIWI-associated piRNAs, we can now include at least 15,000 members of the long non-coding RNA class (Kapranov P et al. (2007) Science 316: 1484-1488; Caeninci P et al. (2005) Science 309: 1559-1563; Djebali S et al. (2012) Nature 489: 101-108; Derrien T et al. (2012) Genome Research 22: 1775-1789; Guttman M et al. (2009) Nature 458: 223-227). Now that we have begun to understand the genomic presence and expression of lncRNA genes, the next goal is to discover their biological functions. As a first step to address this challenge, we applied mouse gene targeting technology, the most powerful tool for determining gene function in mammals, to create a resource of knockout mouse lines for 20 lincRNA genes (Sauvageau M et al. (2013) Elife 2: e01749).
[0277] The structure-function relationships of lincRNAs are not fully understood. For this reason, it is of paramount importance in this initial study to create knockout alleles with deletions that remove most, if not all, of the lincRNA coding capacity to maximize the probability of generating loss-of-function mutations. Ambiguous and incomplete annotation of many lincRNA loci, along with the large number of reported transcripts likely resulting from alternative splicing or transcription start sites, add to the difficulty of knockout allele design. New understanding of molecular features important for lincRNA function will inform the design of the next generation of lincRNA alleles in which sequences important for function are more precisely and directly altered, as well as enable more advanced and flexible interim strategies.
[0278] The primary goal of the lincRNA knockout study was to create alleles that report on the spatiotemporal pattern of gene expression in addition to the abolishing function. Despite having no protein-coding open reading frames as a guide, we succeeded in designing alleles that report on all gene expression of 20 target genes. One of the alleles that did not result in lacZ expression at maturity was Ptgs2os2 (see Figure 2A and Figure 9 for expression in embryos). It is known to be one of the lincRNAs most strongly induced by inflammatory signals (Guttman M et al. (2009) Nature 458:223-227; Carpenter S et al. (2013) Science 341 (6147):789-92). The Ptgs2os2 knockout line should reveal a useful resource for studies on how lincRNA expression responds to infection or other inflammatory insults and what biological role it plays in the process.
[0279] In selecting which lincRNA genes to target for this study, one of the criteria we applied was the expected expression in neural tissues. Ten of the targeted genes showed lacZ reporter expression in the adult brain, ranging from strong expression throughout the brain (Pint), to low gray matter expression in most structures (Tug1), to very restricted expression limited to the colliculus (Crnde) or midline of the hypothalamus (Peril), each with a unique pattern (Figure 3). The diversity and specificity of gene expression in the brain was also evident in other tissues and was similar to what we found using reporter alleles for protein-coding genes. Our lincRNA gene lacZ expression profiling patterns matched the tissue-specific expression found in RNA quantification experiments in wild-type mouse tissues (Sauvageau M et al. (2013) Elife 2: e0174). However, previous quantification methods could not provide the high resolution and cell type resolution of lacZ reporter profiling (Figure 2A), so prior to this study, the exquisite tissue and cell type specificity of lincRNA gene expression had not been appreciated.
[0280] Embryonic expression was a feature shared by all lincRNA genes we examined. lacZ profiling allowed a fine-grained view of the whole embryo revealing a wide range of specific patterns unique to each lncRNA. Examples include the highly specific expression of Trp53cor1 in the whisker placode, lincenc1 in the mammary bud, the superficial expression of Eldr, the limb bud expression of HOTTIP and Hoxa11os, and the ubiquitous expression of Tug1 (Figures 2A and 2B and Figure 9). These varied patterns may indicate common roles of lincRNAs in regulating key events in development.
[0281] Another importance of lacZ profiling is that it can guide and focus the design of phenotypic studies. For example, the highly restricted posterior expression pattern of heterozygous Hotair and HOTTIP embryos suggested that we might find knockout phenotypes in the posterior parts of the body. In line with this expectation, we - / - We observed significant homeotic transfection in the fourth caudal vertebra of mice (Fig. 6). - / - In mice, we demonstrated hindlimb abnormalities, including muscle weakness and skeletal malformations (Fig. 8 and Fig. 10). The Hotair homeotic phenotype was also observed in mice carrying different Hotair knockout alleles (H. Chang, personal communication). We demonstrated that Fendrr expression in heterozygotes is restricted to the lungs of adult mice (Fig. 11, Table 2) and is prominent during embryonic airway development (Fig. 2A). Perhaps not surprisingly, Fendrr homozygotes showed respiratory stress and subsequent perinatal mortality due to incomplete structural maturation of the lung. Our knockout phenotype resembles a rare human fatal pulmonary developmental disease, alveolar capillary dysplasia with pulmonary venous misalignment (ACD / MPV), in which patients show underdeveloped lung lobes and suffer postnatal respiratory distress within minutes to hours after birth (Bishop NB et al. (2011) American Journal of Respiratory and Critical Care Medicine 184: 172-179). At least one ACD / MPV patient has been reported to have an 11 kb deletion in the FOXF1-AS1 gene, which is the human homolog of mouse Fendrr and is expressed in normal human neonatal lung (Szafranski P et al. (2013) Genome Research 23: 23-33). Grote et al. (Groute P et al. (2013), Developmemtal Cll 24: 206-214) reported a notable reported mutant mice with an alteration in the Fendrr gene that caused lethality around E13.75 associated with umbilical hernia, reduced ventral body wall thickness, and cardiac defects resulting in blood accumulation in the right atrium. We did not observe any of these phenotypes. The difference between the phenotypes could be explained by the different allele designs. Our allele was designed to delete Fendrr exon 2 to the end and to start disrupting the promoter that may share the adjacent Foxf1 protein codon gene. The Fendrr allele of Grote et al. (Grote P et al. (2013), Developmental Cell 24:206-214) consisted of a transcription stop element inserted in the first exon and did not contain a reporter gene.
[0282] The most striking adult expression pattern we observed was that of Pint, which showed an increase in the extent and intensity of X-gal staining as mice aged from neonates to mature adults (Figure 4). This striking age-related pattern prompted us to perform a longitudinal analysis of growth rate and overt signs of abnormal health. Compared to WT mice, Pint - / - As the mice aged, they developed progressive hair loss, muscle weakness, and severe spinal cord injury. We found that the lincRNA gene in mice with Pint-positive mice showed signs of vertebral curvature, loss of body fat and bone density, reduced growth rate, and reduced survival. Surprisingly, these results were replicated, albeit to a lesser extent, in heterozygous mice. The range of age-associated phenotypes with abnormal increases in gene expression with age implies that mice require a critical amount of Pint for general maintenance of health and tissue function during normal life span and points out for the first time a potential role for lincRNA genes in physiological aging. Recent studies have shown that Pint is a direct target of p53, linking the p53 pathway and epigenetic silencing via polycomb repressive complex 2 (PRC2) (Marin-Bejar et al., 2013). Mounting evidence implicated the p53 gene as a key player in the control of cellular senescence and aging. Of great interest would be the regulation of Pint and its potential involvement in p53-dependent cellular senescence and biological aging. This could shed light on its important role in physiological aging in mammals with potential clinical implications in human diseases, including diseases related to aging and cancer.
[0283] Our aim in starting this study was not only to shed light on the function of the 20 specific lincRNAs that we selected to mutate genes, but also to better understand the general properties of these lncRNAs as a class. This collection could serve as a seed for a larger effect of mutating more members of the lincRNA gene family. Many lincRNAs were shown to associate with proteins involved in transcriptional regulation at the chromatin level. This could suggest a broad, general, and redundant function in gene expression, similar to the interactions of miRNAs in maintaining tissue-specific expression profiles at the post-transcriptional level. However, our results seem to point in a different direction. The unique phenotypes and highly specific expression patterns described here and shown in Sauvageau et al. (Sauvageau M et al. (2013) Elife 2: e01749) attest to the specific, direct, and restricted functions of lincRNAs. Although this study is only the beginning of the analysis of this collection of knockout mice, it reveals lincRNAs as a new class of functionally encoded molecules that, like proteins, play diverse roles in embryonic development, physiology, and homeostasis of a wide range of mammalian tissues and organs.
Claims
[Claim 1] The method described in the specification.
